

Workshop in Diagnostic Immunohistochemistry Aalborg University Hospital, 29 Sept. - October 1 2021

	ImmuRBMSt86Memcal classification of
Wednesday, Septe	
09:15 – 10:00	Arriva and legis retion, of a DCCT,
10:00 – 10:15 15	Welcome – Introduction
10:15 – 11:00 45	The technical test approach – pre-analytical phase
11:15 – 12:00 45	IHC principles:
	The technical test approach - analytical phase I
12.00 – 12:15 15	Discussion and summary of lectures
12:15 – 13:15 60	Lunch
13:1 5 – 14:00 45	The technical test approach—analytical phase II Discussion and summary of lectures SYCENUS
\	The technical test approach analytical phase II
14,15 – 14:30	Discussion and summary of lectures
14:30 – 15:15 45	IHC principles:
Region Syddanmark	The technical test approach – Tissue tool box for controls
Sv(15:15 T15:35 ebæ 45	Coffee
Jy 45.35 + 16:20 CD CT (45	Validation and verification process for IHC - what, how a DVH - III - what, how and why? (pre-recorded / virtual)
16:20 – 16:30 15	Discussion and summary of lecture
16.30 – 18.00	Social arrangement (optional)
Thursday, Septembe	er 30 th

08:30 - 09:15	45	The unknown primary tumour: IHC for diagnostic use	RR
09:25 – 09:50 25 NordiQC data: Antibody selection, protocols and control		NordiQC data: Antibody selection, protocols and controls	TJ
Henrik-lolager	20	Coffee	
	45	Lung cancer: IHC for diagnostic use	НН
Dept of 14i05 = 11i30 hology	25	NordiQC data: Antibody selection, protocols and controls	HLK
Dept. of Clinical Pathology Vejle Hospital	15	Discussion and summary of lectures	
11:45 – 12:30	45	Breast cancer: IHC for diagnostic use	AVL



Program Wednesday, September 40g cancer Age's standardized

09:30 - 10:00 Incide	ence new cases/100,000 Welcome and introduction	Mortalit	y Death/100.000
10:15 - 11:00 45	Immunohistochemical principles: The technical test approach – pre-analytic	al phase I	
11:05 - 14 ₀ 50 45	Immunohistochemical principles _ The technical test approach – pre-analytic	al phase II ON	_
12:00 - 12045 45	Immunohistochemical principles – The technical test approach - analytical ph	ase I MB	
12:45 - 1 <mark>3</mark> 930 45 /	Lunch 40 –		
13:30 - 14015 45	Immunohistochemical principles: The technical test approach - analytical ph	ase II MB	
14:20 - 1 <u>5</u> 005 45	Immunohistochemical principles _ The technical test approach - post-analytic	al phase I	
15:05 - 15025 20	Coffee 10 –		
15:25 - 16:10 45	Immunohistochemical principles;	SN	
16:15 - 17:00 1950 1960 45	The technical test approach - post-analytic 1970 1980 1990 2000 2010 1970 Immunohistochemical classification of bro tumours	al phase II 30 1970 1980 east AVL	1990 2000 2010
17.00 - 19.00	Social arrangement (optional) – Keglespi	l (<u>Skittles</u>)	

Thursday, Septembers 21st

NORDCAN, Associa	ition of	the Nordic Cancer Registries
n, protocols and	CN	25.3.2019

08:15 - 09:00	45 Males	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN



PRELIMINARY

Wednesday, September 20th Lung cancer

09:30 - 10:00 10:00 - 10:15 New c	ase §/<u>4</u>00	Arrival, coffee interval Deaths/100.00 / ag	ge _N interval
10:15 - 11:00	45	Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON
11:05 - 1 ⁶⁰ 50 500 -	45	Immunohistochemical principles The technical test approach 50 pre-analytical phase II	ON
12:00 - 12:45 400 -	45	Immunohistochemical principles: The technical test approach 400nalytical phase I	МВ
12:45 - 13:30 13:30 - 14:15	45 45	Lunch Immunohistochemical principles:	MP
200 - 14:20 - 15:05	45	The technical test approach 200 nalytical phase II Immunohistochemical principles:	MB SN
100 – 15:05 – 15.25	20	The technical test approach 1090st-analytical phase I Coffee	SIV
15:25 - 16:10_	15- 45 25	Immunohistochemical principles 15 25 35 The technical test approach - post-analytical phase II	4§N 55- 65- 75- 85+
16:15 - 17:00	45	Immunohiseochemical classification of breast tumours	Age AVL
17.00 - 19.00	Eomalos	Social arrangement (optional) – Keglespil (Skittles)	

Thursday, September 21st

····a··baay, b	- p			
08:15 - 09:00	Ma les -	Optimization of antibodies, selection, Protocols ariatic controls – breast tumours	on of the No SN	ordic Cancer Registries 25.3.2019
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	MV	
09:50 - 10:10	20	Coffee		() - 3 Top
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN	
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CN	



11:35 - 12:05

30

PRELIMINARY Program Females Wednesday, September 208h 09:30 - 10:00_{rostata} Arrival, coffee Bryst 15 Welcome and introduction 10:00 - 10:15 Lunge (inkl. luftrør) SN Lunge (inkl. luftrør) 10:15 - 11:00 45 Immunohistochemical principles: Tvktarm ON The technical test approach - pre-analytical phase 11:05 - 11:50 45 Immunohistochemical principles: ON The technical test approach — pre-analytical phase II Endetarm og anus Immunohistochemical principles og centrálnervesystem 12:0)(n)dermænke/drseft, hud 45 MB The technical test approach - analytical phase is Hjerne og centralnervesystem 12:45 - 1383 Ovtkirtel 45 Lunch Bugspytkirtel 13:30 og deflot 45 nerede 45 Immunohistochemical principles: Livmoder MB The technical test approach - analytical phase II Non- Hodakin lymfom Immunohistochemical principles dere og andre urinveje 14:20 - 15:05 45 SN The technical test approach - post-analytical phase I 15:05 - 15.25 Leukæmi 20 Coffee Leukæmi 15:25 - 16:10 Mave 45 Immunohistochemical principles: SN The technical test approach - post-analytical phase II Spiserør 16:15 - 17:00 Lever Immunohistochemical classification of breast^{re} 45 **AVL** Oropharynx tumours 17.00 - 19MQ matose Social arrangement (optional) - Keglespil (Skittles) Skjoldbruskkirtel Thursday, September 21st 08:15 - 09:00 Mundhule 45 Optimization of antibodies, selection, protocols and SN Strube controls - breast tumours 1000 M $\sqrt{^{2000}}$ 3000 4000 5000 6000 4090 2mmunohistochemical classification of the 09:00 - 09:45unknown primary tumour - part I incidence, new cases / 100.000 09:50 - 10:10 Coffee 20 Optimization of antibodies, selection, protocols and 10:10 - 10:40 30 SN controls – unknown primary tumours part I 10:45 - 11:30 45 unknown primary tumour - part II

Optimization of antibodies, selection, protocols and



Program PRELIMINARY

Wednesday, S	epter	mber 20th Lung Carcinoma
09:30 - 10:00		Arrival, coffee Lung Carcinoma
10:00 - 10:15	15	Welcome and introduction SN
10:15 - 11:00	45	Immunohistochemical principles:
		The technical test approach – pre-analytical phase I
11:05 - 11:50	45	Immunohistochemical principles:
		The technical test approach - pre-analytical phase II
12:00 - 12:45	45	Immunohistochemical principles:
		Thentechnical test approach - analytical phase I Neuro-endocrine
12:45 - 13:30	45	Lunch Secondary Basal cell Basement membrane
13:30 - 14:15	45	Immunohistochemical principles:
		The technical test approach - analytical phase II
14:20 - 15:05	45	Immunohistochemical principles:
		The technical test approach - post-analytical phase I
15:05 - 15.25	20	Coffee
15:25 - 16:10	45	Immunohistochemical principles: Alveolus SN
		The technical test approach - post-analytical phase II
16:15 - 17:00	45	Immunohistochemical classification of breast AVL
		tumours
17.00 - 19.00		Social arrangement (optional) – Keglespihi(Skittles) Alveolar
Thursday, Sept	embe	2 2 Probit Alveolus
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and
00.10		controls - breast tumours
09:00 - 09:45	45	Immunohistochemical classification of the MV
		unknown primary tumour – part I
09:50 - 10:10	20	Coffee Alveolus ·
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and
		controlsung careing in a right in
10:45 - 11:30	45	Immunohistochemical classification of the
		unknown primary in the lungrepithelium
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and SN



			Histologic Type and Subtypes	ICDO Code
Program		PRELIM	Epithelial tumors	9140/2
Fiogram		PKEETIJI	Lepidic adenocarcinoma ^e	8140/3 8250/3 ^d
Wodpocday So	ntom	hor 20th	Acinar adenocarcinoma	8551/3 ^d
Wednesday, Se	ptem	ibei 20	Papillary adenocarcinoma	8260/3
09:30 - 10:00		Arrival coffee	Micropapillary adenocarcinoma ^c Solid adenocarcinoma	8265/3 8230/3
		Arrival, coffee	Invasive mucinous adenocarcinoma ^e	8253/3 ^d
10:00 - 10:15	15	Welcome and introd		8254/3 ^d
10:15 - 11:00	45	Immunohistochemi	cal principles:	8480/3 8333/3
		The technical test a	IDD roaGa cacione-analytical pha	S e 44 I 5
11:05 - 11:50	45	Immunohistochemi	cal principles:	8256/3 ^d
		The technical test a	pproach lesionspre-analytical pha	ase II
12:00 - 12:45	45	Immunohistochemic	cal participates hyperplasia	$8250/0^d$
		The technical test a	pproachucinous analytical phase I	8250/2 ^d 8253/2 ^d
12:45 - 13:30	45	Lunch	Squamous cell carcinoma	8070/3
13:30 - 14:15	45	Immunohistochemi	Keratinizing squamous cell carcinoma ^e	8071/3 8072/3
malianant anithali	٠. ٠	The technical test a	Basaloid squamous cell carcinoma ^c pproach estonanalytical phase	$\Pi^{8083/3}$
malignant epitheli	45 LU	Inmunohistochemic	calcupidhnicuples:	8070/2
15:05 - (carcinom:	(zs	The technical test a	pproduced characteristics and street in the street of the	aşe,41/3
15:05 – 15.25	20	Coffee	Large cell neuroendocrine carcinoma Combined large cell neuroendocrine carcinoma	8013/3 8013/3
15:25 - 16:10	45	Immunohistochemi	cal ^c principles:	8240/3
		The technical test a	pproachion and post-analytical ph	a se ⁄II
16:15 - 17:00	45	Immunohistochemic	cal classification of breast	$8040/0^{d}$
		tumours	Large cell carcinoma	8012/3
17.00 - 19.00		Social arrangement	: (Optional) Keglespil (Sk	
Thursday Conto	mha.	. 24 st	Pleomorphic carcinoma Spindle cell carcinoma	8022/3 8032/3
Thursday, Septe	IIIDEI	21	Giant cell carcinoma	8031/3
08:15 - 09:00	45	Optimization of anti	ibodiesy selection, protocol	s ^{8980/3} s æ nd
		controls – breast tu		8082/3
09:00 - 09:45	45		cals Classification of the	$8023/3^d$
		unknown primary to	umovurepidermeidaarduoi t a Adenoid cystic carcinoma	8430/3 8200/3
09:50 - 10:10	20	Coffee	Epithelial-myoepithelial carcinoma Pleomorphic adenoma	8562/3 8940/0
10:10 - 10:40	30		ibodies, selection, protocol	
		controls – unknown	primary tumours part I	
10:45 - 11:30	45	Immunohistochemie	cal classification of the	
		unknown primary to	umour – part II	
11:35 - 12:05	30		ibodies, selection, protocol	s and

BLE 1. (Continued)	
--------------------	--

TABLE 1. 2015 WHO Classification of Lung Tumors a,b,c

listologic Type and Subtypes	ICDO Cod
Papillomas	
Squamous cell papilloma	8052/0
Exophytic	8052/0
Inverted	8053/0
Glandular papilloma	8260/0
Mixed squamous and glandular papilloma	8560/0
Adenomas	
Sclerosing pneumocytoma ^e	8832/0
SANcolar adenoma	8251/0
Papillary adenoma	8260/0
Mucinous cystadenoma	8470/0
Owous gland adenoma	8480/0
lesenchymal tumors	
Pulmonary hamartoma	$8992/0^{d}$
Chondroma	9220/0
P_Colnatous tumors ^e	
Lymphangioleiomyomatosis	9174/1
PEComa, benign ^e	8714/0
M Bear cell tumor	8005/0
PEComa, malignant ^e	8714/3
Congenital peribronchial myofibroblastic tumor	8827/1
Diffuse pulmonary lymphangiomatosis	
Inflammatory myofibroblastic tumor	8825/1
Epithelioid hemangioendothelioma	9133/3
Yeu oulmonary blastoma	8973/3
Synovial sarcoma	9040/3
Pulmonary artery intimal sarcoma	9137/3
Editionary myxoid sarcoma with EWSR1–CREB1 translocations of the bit below the sarcoma with EWSR1–CREB1 translocations of the bit below the sarcoma with EWSR1–CREB1 translocations of the bit below to be sarcoma with EWSR1–CREB1 translocations of the bit below to be sarcoma with EWSR1–CREB1 translocations of the bit below to be sarcoma with EWSR1–CREB1 translocations of the bit below to be sarcoma with EWSR1–CREB1 translocations of the bit below to be sarcoma with EWSR1–CREB1 translocations of the bit below to be sarcoma with EWSR1–CREB1 translocations of the bit below to be sarcoma with EWSR1–CREB1 translocations of the bit below to be sarcoma with EWSR1–CREB1 translocations of the bit below to be sarcoma with EWSR1–CREB1 translocations of the bit below to be sarcoma with EWSR1–CREB1 translocations of the bit below to be sarcomatically be sarcomatically below to be sarcomatically be sarcomatically below to be sarcomatically b	8842/3 ^d
Myoepithelioma	8982/0
Myoepithelial carcinoma	8982/3
ymphohistiocytic tumors	
Extranodal marginal zone lymphomas of mucosa-associated Clymphoid tissue (MALT lymphoma)	9699/3
Diffuse large cell lymphoma	9680/3
Lymphomatoid granulomatosis	9766/1
Intravascular large B cell lymphoma ^c	9712/3
Almorary Langerhans cell histiocytosis	9751/1
Erdheim-Chester disease	9750/1
umors of ectopic origin	
Germ cell tumors	
Teratoma, mature	9080/0
Teratoma, immature	9080/1
Intrapulmonary thymoma	8580/3
Melanoma	8270/3
Meningioma, NOS	9530/0
Least tic tumors	

"The morphology codes are from the ICDO." Behavior is coded /0 for benign tumors, I courspecified, borderline or uncertain behavior, /2 for carcinoma in situ and grade III machi deilal neoplasia, and /3 for malignant tumors.
"The classification is modified from the previous WHO classification³ taking into

count changes in our understanding of these lesions.

This table is reproduced from the 2015 WHO Classification by Travis et al.1

dThese new codes were approved by the International Agency on Cancer Research/ WHO Committee for ICDO.

eNew terms changed or entities added since 2004 WHO Classification.3 LCNEC, large cell neuroendocrine carcinoma, WHO, World Health Organization;

MV

SN



11:35 - 12:05

30

	Ab.		Histologic Type and Subtypes	ICDO Code
Program		PRELIM:	Epithelial tumors	8140/3
Wadaaaday C.			Lepidic adenocarcinoma ^e Acinar adenocarcinoma	8250/3 ^d 8551/3 ^d
Wednesday, Se	ptem	iber 20'''	Papillary adenocarcinoma	8260/3
09:30 - 10:00		Arrival coffee	Micropapillary adenocarcinoma ^e Solid adenocarcinoma	8265/3 8230/3
		Arrival, coffee	Invasive mucinous adenocarcinoma ^e	8253/3 ^d
10:00 - 10:15	15	Welcome and introd	uctiomixed invasive mucinous and nonmucinous adenocarcinoma	8254/3 ^d
10:15 - 11:00	45	Immunohistochemic	al principles ma	8480/3
		The technical test ar	proachdemocapicar-analytical phas	5e 81 I 4/3
11:05 - 11:50	45	Immunohistochemic	Minimally invasive adenocarcinoma ^c	8256/3 ^d
		The technical test ar	proach, pre-analytical phas	$\mathbf{se}^{8257/3^d}$
12:00 - 12:45	45	Immunohistochemic	al principal dipensions hyperplasia	$8250/0^d$
		The technical test ar	proachimicinanalytical phase I	8250/2 ^d
. 12:45 - 13:30	45	Lunch	Mucinous Squamous cell carcinoma	8253/2 ^d 8070/3
Adenocarcinoma (45%)	45		Keratinizing squamous cell carcinoma ^c	8071/3
10.00 1.110			Basaloid squamous cell carcinoma ^e	8072/3 8083/3
Squamous carcinoma (1	,		Basalqid squamous cell carcinoma ^r Dproachere tesianalytical phase II	8070/2
Large tell nellioendocri	n e 5cai	r emomo l(i b%) chemic	al New behild content of the content	
	9/\	The technical test a	proadched small pha	se ⁰⁴ 1/3
Small _ı <u>çell carçin</u> gma (12	<u> 2</u> 6	Coffee	Large cell neuroendocrine carcinoma Combined large cell neuroendocrine carcinoma	8013/3 8013/3
15:25 - 16:10	45	Immunohistochemic	al principles:	
		The technical test ar	Dproach carein post-analytical pha	8240/3 S@ 24]/]
16:15 - 17:00	45	Immunohistochemic	proach post-analytical pha al classification of the cast	$8040/0^{d}$
		tumours	cell hyperplasia Large cell carcinoma	8012/3
17.00 - 19.00			(optionalia ir)inomas Keglespil (Skit	
		_	Pleomorphic carcinoma	8022/3
Thursday, Septe	mbe	r 21 st	Spindle cell carcinoma	8032/3 8031/3
			Giant cell carcinoma Carcinosarcoma	8980/3
08:15 - 09:00	45	•	podies, selection, protocols	and
		controls – breast tur	nour and Unclassified carcinomas Nour Sphoepithelioma-like carcinoma	8082/3
09:00 - 09:45	45	Immunohistochemic	al classification of the	8023/3 ^d
		unknown primary tu	mou ^M rcoepide paid recinoma	8430/3 8200/3
09:50 - 10:10	20	Coffee	Epithelial-myoepithelial carcinoma	8562/3
10:10 - 10:40	30	Optimization of anti	podies, selection, protocols	8940/0 and
_0.10		•	primary tumours part I	(33.7.341)
10:45 - 11:30	45		al classification of the	
10.45 - 11.50	73			
		unknown primary tu	mour – part II	

Optimization of antibodies, selection, protocols and

BLE	1.	(Continued)

TABLE 1. 2015 WHO Classification of Lung Tumors^{a,b,c}

stologic Type and Subtypes	ICDO Code
Papillomas	
Squamous cell papilloma	8052/0
Exophytic	8052/0
Inverted	8053/0
Glandular papilloma	8260/0
Mixed squamous and glandular papilloma	8560/0
Adenomas	
Sclerosing pneumocytomae	8832/0
Alveolar adenoma	8251/0
Papillary adenoma	8260/0
Mucinous cystadenoma	8470/0
Lucous gland adenoma	8480/0
esenchymal tumors	
Pulmonary hamartoma	$8992/0^{d}$
Chondroma	9220/0
PEComatous tumors ^e	
Lymphangioleiomyomatosis	9174/1
PEComa, benign ^e	8714/0
BClear cell tumor	8005/0
PEComa, malignant ^e	8714/3
Congenital peribronchial myofibroblastic tumor	8827/1
Diffuse pulmonary lymphangiomatosis	
Inflammatory myofibroblastic tumor	8825/1
Epithelioid hemangioendothelioma	9133/3
propulmonary blastoma	8973/3
Synovial sarcoma	9040/3
Pulmonary artery intimal sarcoma	9137/3
Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation ^e Myoepithelial tumors ^e	8842/3 ^d
Myoepithelioma	8982/0
Myoepithelial carcinoma	8982/3
mphohistiocytic tumors	
Extranodal marginal zone lymphomas of mucosa-associated \[\begin{align*} \begin{align*} \begin	9699/3
Diffuse large cell lymphoma	9680/3
Lymphomatoid granulomatosis	9766/1
Intravascular large B cell lymphomae	9712/3
Punonary Langerhans cell histiocytosis	9751/1
Erdheim-Chester disease	9750/1
mors of ectopic origin	
Germ cell tumors	
Teratoma, mature	9080/0
Teratoma, immature	9080/1
Intrapulmonary thymoma	8580/3
Melanoma	8270/3
Meningioma, NOS Instatic tumors	9530/0

The morphology codes are from the ICDO.² Behavior is coded /0 for benign tumors, if or unspecified, borderline or uncertain behavior, /2 for carcinoma in situ and grade III May ithelial neoplasia, and /3 for malignant tumors.

The classification is modified from the previous WHO classification³ taking into account changes in our understanding of these lesions.

^cThis table is reproduced from the 2015 WHO Classification by Travis et al.¹

"These new codes were approved by the International Agency on Cancer Research/ O Committee for ICDO.


LCNEC, large cell neuroendocrine carcinoma, WHO, World Health Organization;

MV




PRELIMINARY

Wednesday, Se	epte	mb <u>e</u> r 20 th	
09:30 - 10:00	-	ADiagnostic sampling	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase I	ON
11:05 - 11:50	4 5.	In in property temes all principles: The tempical test approach – pre-analytical phase II	ON
12:00 - 12:45	2 .	Industrial principles: The ten of	MBTNM)
12:45 - 13:30	45	Lunch	()
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	МВ
14:20 - 15:05	45	Immunohistochemical perinciples: Stage IA The technical test approach post analytical phase I in situ (AIS) Tx, Nx should be used only if no Tis No Tis No	Stage IB
15:05 - 15.25	20	All Stage 1-III tumors are M0 COFFEE Tx, Nx should be used only if no Tis N0 Tis N0 Tib N0 Tib N0	
15:25 - 16:10	45	indimonal mobilet ochemical heinen lage To a financial	SN T2a _{Centr} N0
16:15 - 17:00	45	MImmunohistochemical classification of breast symptoms and physical exam infortable and physical examination and physical exam infortable and physical exam infor	T2a _{Vise PI} N0 T2a N0 (>3 ≤4 cm)
17.00 - 19.00	L	Social arrangement (optional) Keglespil (Skittles)	
Thursday, Septe	emb	er 21 st	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	⊸SN
00.00 00.45	45	controls breast tumours	MV
09:00 - 09:45	45	unknown primary tumour - part I	T3 _{Satell} N0
09:50 - 10:10	20	Coffee T3 _{lav} N0 {	1
10:10 - 10:40	30	Optimization of antibodies, selection protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the	MV
11.05.10.05		unknown primary tumour – part II	•
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN











11:35 - 12:05

30

PRELIMINARY


riogiani		FICEIPHIANN		
Wednesday, September 20 th Bronchoscope				
09:30 - 10:00		Arrival, coffee		
10:00 - 10:15	15	Welcome and introduction	SN	
10:15 - 11:00	45	Immunohistochemical principles. The technical test approach – pre-analytical phase I	ON	
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach - pre-analytical phase II	on Br	
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	мв Д	
12:45 - 13:30	45	Lunch		
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	МВ	
14.20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN	
15:05 - 15.25	§ 0	Coffee		
15:25 - 16:10	4 5	Immunohistoch <mark>emical principles:</mark>	SN	
16.15 17.00	45	The technical test approach - post-analytical phase II		
16:15 - 17:00	45	Immunoristoch <mark>emical classification of breast tumours</mark>	AVL	
17.00 - 19.00		Social arrangement (optional) – Keglespil (<u>Skittles</u>)	7/4/2	
Thursday, Septe	embe	r 21 st		
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN	
09:00 - 09:45	45	Immunohistochemical classification of the	MV	
BANK AND A VINCE		unknown primary tumour – part I		
09:50 - 10:10	20	Coffee		
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN	
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV	
		, , , , , , , , , , , , , , , , , , , ,		

Optimization of antibodies, selection, protocols and

Bronkialwash
Brushbiopsy*
EBUS**


EUS*

Biopsy §






Program		PRELIMINARY	
Wednesday, Sep	otem	nber 20 th	
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase I	.
11:05 - 11:50	45	Immunohistochemical principles:	ON
12.45	4E	The technical to roach – pre-analytical phase II	
12:45	45	Immunohistoch principles: The technical technical roach - analytical phase I	MB
13:30	45	Lunch	
	45	Immunohistoch principles:	MD
		The technical terroach - analytical phase II	MB
15:05	45	Immunohistoch principles:	SN 🧖
Contract of		The technical technical phase I	311
	20	Coffee	
16:10	45	Immunohistoch principles:	SN
1	TO.	The technical terms roach - post-analytical phase II	
17:00	45	Immunohistoch classification of breast	AVL
19.00		tumours Social arranger (Skittles)	
ACROSING MICHIGAN	500		
day, Septen	nbe	ALCOHOL: LINE AND ADDRESS OF THE ADD	
09:00	45	Optimization of dies, selection, protocols and	SN
4144		controls – brea	
09:45	45	Immunohistoch classification of the	MY
00:50 10:10	20	unknown primary tumour – part I Coffee	
	20 30	Optimization of antibodies, selection, protocols and	A warman and a second s
10.10 - 10.40	J U	controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the	
		unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN





PRELIMINARY EBUS, EUS

Wednesday, September 20 th			
09:30 - 10:00		Arrival, coffee	41
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase I	
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase []	DN / ,-
12:00 - 12:45	45	Immunohistochemical principles:	11/11
12.00 - 12.43	73	The technical test approach - analytical phase I	MB
12:45 - 13:30	45	Lunch	-
13:30 - 14:15	45	Immunohistochemical principles:	MA
		The technical test approach - analytical phase II	MB
14:20 - 15:05	45	Immunohistochemical principles:	SÑ
		The technical test approach - post-analytical phase I	SIN
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistochemical principles:	SN
		The technical test approach - post-analytical phase II	514
16:15 - 17:00	45	Immunohistochemical classification of breast	AVL
17.00 - 19.00		tumours Social arrangement (optional) - Keglespil (Skittles)	
	_		
Thursday, Sep	otembe	er 21 st	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	SN
00 00 00 15		controls – breast tumours	
09:00 - 09:45	45	Immunohistochemical classification of the	MV
09:50 - 10:10	20	unknown primary tumour - part I Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	
10.10 10.10	30	controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the	N 43 7
-	_	unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN






PRELIMINARY

Wednesday, September 20th

wednesday, sep	delliber 20	
09:30 - 10:00	Arrival, coffee	Fine needle biopsy
10:00 - <u>1</u> 0:15	Welcome and introduction	SN ' '
10:15 - Googse need	Welcome and introduction biውթ\$ኒ/unohistochemical principles: The technical test approach – pre-analytical phase	ON
11:05 - 11:50 A	Immunohistochemical principles: neediae technical test approach – pre-analytical phase	ON ON
12:00 - 12:45	into the mical test approach - analytical phase I	МВ
12.05 13.30	15 tumpfunch	
13:30 - 14:152	Immunohistochemical principles:	MB
Body 15.05	The technical test approach - analytical phase II	HA THE STATE OF TH
14w20 - 15:05	Immunohistochemical principles: The technical test approach - post-analytical phas	SN SN
15:05 - 15.25 _{mor} 2	Coffee	eı
15:25 - 16:10	mmunohistochemical principles:	5 1 (1) 18 0 19 19 19
	The technical test approach - post-analytical phas	e II SN 🐡
16:15 - 17:00	Immunohistochemical classification of breast	
A STATE OF THE STA	tumours (/	AVL
17.00 - 19.00	Social arrangement (optional) – Keglespil 🔁 🔀	<u>es)</u>
Thursday, Septen	nber 21 st	



,, .			
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN S
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN




11:35 - 12:05

30

PRELIMINARY Program

wednesday, septer matomical specimen

	_		
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	I 1 • 45 L	Immunohistochemical principles:	ON
11:05 - 11:50	HIŞT	he chi a test approach – pre-analytical phase I immunonituschemical principles: The technical test approach – pre-analytical phase II	Cytologi ON
2:00 -12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
12:45 - 13:30	Fixation	Lunch	



The technical test approach - post-analytical phase II 45 Immunohistochemical classification of breast

AVL tumours


Optimization of antibodies, selection, protocols and

SN


17.00 -		Social arrangement (optional) – Keglespil (<u>Skittles</u>)	
Thurse	day, Septemb	optimiza Visua lization	•
08:15 -	09:00 45	Optimization of Intibided, selection Circles of Controls – breast tumours	SN
09:00 -	09:45 45	Immunohistochemical classification of the unknown primary (Stains)	MV
09:50 -	10:10 20	Coffee (Stalling)	
10:10 -	10:40 30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 -	11:30 45	Immunohistochemical classification of the	MV

unknown primary tumour - part II

Patient selection in lung cancer: Evolution over time



Patient selection in lung cancer: Evolution over time







PRELIMINARY

Wednesday, September 20th

N9130 - 10:00	Arrival, coffee	
Morphology	Welcome and introduction	SN
10:15 - 11:00 45	Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON
11:05 - 11:50 45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON



12:00 - 12:45 45	Immunohistochemical principles:
0.000	The technical test approach - analytical phase I
12:45 - 13:30	Lunch
13:30 - 14:15 45	Immunohistochemical principles:
	The technical test approach - analytical phase II
14:20 - 15:05 45	Immunohistochemical principles:
	The technical test approach - post-analytical phase I
15:05 - 15.25 20	Coffee
15:05 - 15:25 20 15:25 - 16:10 45	Immunohistochemical principles:
A STATE OF THE STA	The trade is a life to a service of the service of



The technical test approach - post-analytical phase II

16:15 - 17:00

Adenocarcinoma

Immunohistochemical classification of Breast Cell

AVL
tumouns

neuroendocrine carc.

Small cell carcinoma

17.00 – 19.00 Social arrangement (optional) – Keglespil (Skittles)

Thursday, September 21st Language Carcino, maco (NSCLC)

	controls – breast tumours	511
09:00 - 09:45 45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10 20	Coffee	
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 – 11:30 45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and	SN



17.00 - 19.00

11:35 - 12:05

PRELIMINARY

Wednesday, September 20th

20

30

TIAdenacarcinomanhar 218 duamous carcinoma

09:30 - 10:00 Arrival, coffee Welcome and introduction SN

Immunorlistoche nical principles: ON The technical test approach - pre-analytical phase I

11:05 - 11:50 45 Immunohistochemical principles: ON The technical test approach – pre-analytical phase II

Immunohistochemical principles: 12:00 - 12:45 45

The technical test approach - analytical phase I Lunch

45 Lunch 12:45 - 13:20 Immunohistochemical principles: 45

The technical test approach - analytical phase

Immunohistochemical principles:

The technical test approach - post-analytical phas Coffee

Immunohistochemical principles:

The technical test approach - post-analytical phase

Immunohistochemical classification of breas tumours

Social arrangement (optional) - Kegle

unknown primary tumour - part II


SN

Kromogen (farvestof)

Visualiseringssystem Sekundært antistof Primært antistof

Cellens cytoplasma Cellekerne





Small cell carcinoma


indisday, septe	HIDC	neuroendocr	ine carc	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN	
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	dendo:	crine carc.
09:50 - 10:10	20	Coffee		
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN	
10:45 - 11:30	45	Immunohistochemical classification of the	MV	

Optimization of antibodies, selection, protocols and



PRELIMINARY

Wednesday, September 20th




Social arrangement (optional) - Kegleangeskielles) 17.00.- 19.00

Adenocarcinoma

Thursday, September 21st Squamous carcinoma neuroendocrine carc

08:15 - 09:00 45 Optimization of antibodies, selection, protocols and controls - breast tumours Non Small Cell Intungation and

		unknown primary tumour – part 1	•
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN




Kromogen (farvestof)


Visualiseringssystem Sekundært antistof Primært antistof


Cellens cytoplasma Cellekerne


cd56





Small cell carcinoma



































Thursday, September 21st

08:15 + 09:00 09:00 + 09:45	45°	Optimization of antibodies, selection, protocols and controls – breast tumours Immunohistochemical classification of the	SN MV
69750 - 10 10C	20	unknown primary tumour – part I Coffee	
10.10 - 10.40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30 ++f +	45	Immunohistochemical classification of the	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CNI

ADC marker +

SQCC marker +

NSCLC, NOS possible adenosquamous ca.



PRELIMINARY

Wednesday, September 20th

-	V7

09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemical principles:	ON
40.00	20 6 5 1	The technical test approach – pre-analytical phase II	
12:00 - 12:45	45	Immunohistochemical principles	Adenocarcinoma
12:45 - 13:30	45	The technical test approach - analytical phase I Lunch	
13:30 - 14:15	45	Immunohistochemical principles:	
15.30 - 14.13	255	The technical test approach - analytical phase II	MB
14:20 - 15:05	45	Immunohistochemical principles:	
	POIL-	The technical test approach - post-analytical phase I	SN
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistochemical principles:	SN
The Market of Landin		The technical test approach past Tital phase II	Siv
16:15 - 17:00	45	Immunohistochemical classification of breast	AVL
	200	tumours	
1/.00 - 19.00	2000	Social arrangement (optional) – Keglespil (<u>Skittles</u>)	

Thursday, September 21st

08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45	45	controls – breast tumours Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	controls – unknown primary tumours part I Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CN



PRELIMINARY

Wednesday, September 20th

	• •	•		
	09:30 - 10:00		Arrival, coffee	
	10:00 - 10:15	15	Welcome and introduction	SN
	10:15 - 11:00	45	Immunohistochemical principles:	ON
	11:05 - 11:50	45	The technical test approach – pre-analytical phase I Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON
* 250	12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
0	12:45 - 13:30	45	Lunch	
	13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	МВ
******	14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN
į	15:05 - 15.25	20	Coffee	
	15:25 - 16:10	45	Immunohistochemical principles: The technical test approach past-saytical phase II	SN
200	16:15 - 17:00	45	Immunohistochemical classification of breast tumours	AVL
b	17.00 - 19.00	369.24	Social arrangement (optional) – Keglespil (<u>Skittles</u>)	

Thursday, September 21st

08:15 - 09:00	45	Optimization of antibodies, selection, protocols and
09:00 - 09:45	45	controls – breast tumours Immunohistochemical classific to the unknown primary tumour – part I
09:50 - 10:10	20	Coffee
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and
		controls – unknown primar <mark>y tumours pa</mark> rt I
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II
		unknown primary tumour - part II
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and

SN

MV

Squamous carcinoma

SN



PRELIMINARY

Wednesday, September 20th

wednesday, se	hren	ibei 20	
09:30 - 10:00 10 Propiems	S1 5	Arrival, coffee Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles: The technical test approach representation beed.	P63+
11:05 - 11:50	45	The technical cost approach - pre-analytical phase II	POST ON
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
12:45 - 13:30	45	Lunch	
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	МВ
14:20 - 15:05	45	Immunohistochemica <mark>l principles: The technical test approach - post-a</mark> nalytical phase I	SN
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistoche <mark>mical principles: 2</mark> The technical tes <mark>t approach - post-analytical phase II</mark>	SN
16:15 - 17:00	45	Immunohistochemical classification of breast tumours	AVL
17.00 - 19.00		Social arrangement (optional) - Keglespil (<u>Skittles</u>)	
Thursday, Septe	embe	r 21 st	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN

08:15 - 09:00 4 :	controls – breast tumours	SN
09:00 - 09:45 4 !	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10 2 6	Coffee	
10:10 - 10:40 3 0	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30 4 !	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05 3 0	Optimization of antibodies, selection, protocols and	SNI

p40 is the Best Marker for Diagnosing Pulmonary Squamous Cell Carcinoma: Comparison With p63, Cytokeratin 5/6, Desmocollin-3, and Sox2

Takahiro Tatsumori, MD,*† Koji Tsuta, MD, PhD,* Kyohei Masai, MD,* Tomoaki Kinno, MD,*
Tomoko Taniyama, MD,* Akhliko Yoshida, MD, PhD,* Kenji Suzuki, MD, PhD,†
and Hitoshi Tsuda, MD, PhD*



PRELIMINARY

Wednesday, September 20th

	, образ			
09:30 - 10:00		Arrival, coffee		
	MSļ⁵	Welcome and introduction	SN	
10:15 - 11:00	45	Immunohistochemical principles:	ON -	
11:05 - 11:50	45	Aldernocaterical principles and		•
		The technical test approach – pre-ana	alytical phase II	
12:00 - 12:45	45	Immunohistochemical principles:	МВ	
		The technical test approach - analytic	cal phase I	
12:45 - 13:30	45	Lunch No. Cases (%	(b) Immunoreactivity	
13:30 - 14:15	M 4. k er	Immunohi្អត្តអ្នchemical principles:	Positive MB	Mean Staining Score (0-300)
SOC	p40	The technical test approach - analytic	tal phase II 153 (96.8)	169
14:20 - 15:05	p63 45	Immunohistochemical principles:	150 (07.4)	237
15:05 - 15.25	p40 20	The technical test approach - post-an	alytical phase I	1.3
	p63 20	419 305 (72.8)	114 (27.2)	16.9
15:25 - 16:10	¹ 45	Immunohistochemical principles:	SN	
		The technical test approach - post-an	alytical phase II	
16:15 - 17:00	45	Immunohistochemical classification of	of breast AVL	
		tumoursskin breast prostate	AVL	
17.00 - 19.00	D43 V	Social arrangement (diptional) - Keg	lespil (<u>Skittles</u>)	
Thursday, Se	ptembe	r 21st		

Optimization of antibodies, selection of antibodies of antibo 08:15 - 09:00 45 controls - breast tumours Immunohistochemical classification of the My nohistochemical classification of 09:00 09:45 mitment Cytokeratin 5/6, Desmocollin-3, and Sox2 ectoderm unknown primary tumour – part I 20 liferati Coffee 09:50 - 10:10 Takahiro Tatsumori, MD,*† Koji Tsuta, MD, PhD,* Kyohei Masai, MD,* Tomoaki Kinno, MD,* Optimization of antibodies, selection, protocois and skiliko Yoshida, MD, PhD, Kenji Suzuki, MD, PhD, † 10:10 - 10:40 30 an Mitoshi Tsuda, MD, PhD* controls - unknown primary tumours part I

10:45 – 11:30

45 Immunohistochemical classification of the unknown primary tumour – part II

11:35 – 12:05

30 Optimization of antibodies, selection, protocols and SN



PRELIMINARY

Wednesday, September 20th

2012 10 Table 2 Se	ensitiyjtw _{rs} pecificity, PPV and NPV o	f markers us	ed in this	
	,	SN	ca iii diis	
10:15 = 11:00	OSfffV@ダもではできます。 Immunohistochemical principles:			
	Sulling to sent and the sent of the sent o	PPV (%)	NPV (%)	
Дироз (р10)	BC Cechnica10€st(166)r106\$h - pr1600a(136291312)se	ı 100 (16/16)	100 (32/32)]
12:00 - 12:45 45 / p63	Immunohistochemical principles:	804(916/20)	100 (28/28)	
12:45 - 13:30 13:30 - 14:15 45	Synch 81 (13/16) 100 (32/32) Immunohistochemical principles:	100 (13/13)	91 (32/35)	
34ßE12	1316 Ctechnica 914 \$(1455)⊅1660)ch - ana4√7i(a155)/a32)II	47 ^{MB} (15/32)	94 (15/16)	
14:20 - 15: <u>05</u> TTF1	Immunohistochemical principles:	_{e I} 87 ^S (120/23)	80 (20/25)	•
15:05 - 15.25 15:25 - 16:10 A 20	Coffee 64 (16/25) 100 (23/23) Immunohistochemical principles:	100 (16/16)	72 (23/32)	
CK7	TAE technica10est(25p/25ch - post35a(85/23b)hase	e II 63 (25/40)	100 (8/8)	
16:15 - 17:00 45 CK8/18	Immunohistochemical classification of breast tagain 100 (25/25) 35 (8/23)	63 ^A (25/40)	100 (8/8)	
$17.00 - 19.\overline{09}_{\text{Sensitivity}} = 7$	TP/TP+FN; Specificity = TN/TN+FP; Positive	es) predictive value	(PPV) = TP/	
Thursday, September	Tve predictive value (NPV) = TN/TN+FN. FN	indicates false n	negatives: FP.	
08:15 - 09:00 lse positive	s. Ontimization of antibodies, selection, protocols a controls – breast tumours	and SN	,	
09:00 - 09:45 45	Immunohistochemical classification of the Local Clin Exp		624	
09:50 - 10:10 20	Coffee			
10:10 - 10:40 30	Optimization of antibodies, selection, protocols	/ Article and CK5/SNTTF-1 and	I nansin A a reliabl	e nanel to
10:45 - 11:30 45	controls – unknown primary tumours part Np63 Immunohistochemical classification of the	e non-small cell lui	ng cancer in biopsy	specimens
	unknown primary tumour – part II	1 1 v		
11:35 - 12:05 30	Optimization of antibodies, selection, protocols	i Wang, Yan Peng, Bo Tian, Lei Penį BNC SN	g, Da-Chuan Zhang	



11:35 - 12:05

30

Program	PRELIMINARY
Wednesday, Septe	ember 20 th
_{09:30 - 10:} Table 2. S	Sensitivity pecificity, PPV and NPV of markers used in this
10:00 - 10:15 tudy [%5	(postfione for the state of th
	· · ·
Marker 11:05 - 11:50 45	Immilinohictochomical neincinios · · · · · · · · · · · · · · · · · · ·
Δινρος (μπι	0) 180Gechnica1006 (16分分6) - pr全分6(30分32分5e II 100 (16/16) 100 (32/32)
12:00 - 12:45 **45 p63	FreGechnical Pest 16 prise in analytical straight 80 (16/20) 100 (28/28)
12:45 - 13:30 ₄₅ /5/6 45 13:30 - 14:15 45	504 61115/101 100152/321 100115/151 91152/331
0.40=40	ቼ (C technica) ነቀ \$ (<u>15</u> /16)
34βΕ12 14:20 – 1 <mark>5:05 45 TTF1</mark>	Immunohistochemical principles: The technical lest approximate principles: The technical lest approximate principles: The technical lest approximate principles:
15:05 - 15.25 15:25 - 16:10 20	Immunohistochemical principles: 100 (23/23) 100 (10/10) 72 (23/32)
CK /	T AE technica 10 65(25/25),25分,25分,25分。25分。100(8/8)
16:15 - 17:00 45 CK8/18	Immunohistochemicál classification of breast tampours 100 (25/25) 35 (8/23) 63 (25/40) 100 (8/8)
17.00 - 19.00 Sensitivity =	= TP/TP+FN; Specificity = TN/TN+FP; Positive predictive value (PPV) = TP/
Thursday, Septemb	ber 21 st gative predictive value (NPV) = TN/TN+FN. FN indicates false negatives; FP,
08:15 - 09:00 false positive	ves; This in the state of the s
09:00 - 09:45 45	
09:50 - 10:10 20	C offee
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and article controls – unknown primary tumours part 1963, CK5/SNTTF-1 and napsin A, a reliable panel to
10:45 - 11:30 45	Immunohistochemical classification of the ubtype non-small cell lung cancer in biopsy specimens
10110 11100 19	unknown primary tumour – part II

Optimization of antibodies, selection, protocols and CNI



PRELIMINARY

Wednesday, September 20th

09:30 - 10:00	Arrival, coffee	
	Welcome and introduction	SN
10:15 - 11:00 4		ON E
11:05 - 11:50 4	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON 3
12:00 – 12:45 4	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
12:45 - 13:30 4	Lunch	
13:30 - 14:15 4	Immunohistochemical principles: The technical test approach - analytical phase II	МВ
14:20 – 15:05 4	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN _
15:05 – 15.25 2	Coffee	
15:25 - 16:10 4	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN

diagnosis between primary and metastatic Social arrangement (optional) - Keglespil (Skittles)

17.00 - 19.00

Thursday, September 21st

30

11:35 - 12:05

carcinoma

08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the	MV
09:50 - 1 Oth	e120(a	unknown primary tumour – part I adeno Carcinomas are poor optimization of antibodies, selection, protocols and	ositive for ttfl
10:10 - 10:40	30 \	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the	MV

Optimization of antibodies, selection, protocols and

SN

unknown primary tumour – part II



PRELIMINARY

Table 1

Wadnasdammentambara 10th chemistry results

Wednesday, magnetic minero 20 to chemistry results.						
09:30 - 10:00	Arrival, coffee					
10:00 - 10:15 15		Total cases	SPT24	SN 8G7G3/1	1 <i>P</i>	
10:15 - 11:00 45	Immunohistochemical princip The technical test approach -	oles: - pre-analytica	l phase I	ON		
11:05 – 11:50 Adenoca A:5 10m	aImmunohistochemical princip	oles185	134 (72.4%)	on ¹²¹ (65.49)	%) 0.08	
12:00 - 12:45 Large Cell	The technical test approach - Immunohistochemical princip	- pre-analytica ples:	l phase II 22(46.8%)	17(36.2%		
Carcinoid	The technical test approach -		as ė 41(60.8%)	MB 4(17.4%)	0.003	
12:45 - 13:30	Lunch Immunohistochemical princip	97 nles:	14(16.8%)	1(1.0%)	0.003	
Unclassified	The technical test approach -		ase0(#45.5%)	MB _{7(31.8%)}	0.26	
14:20 - 15:05 _{Bladder} 45	Immunohistochemical princip The technical test approach -		5 (5.1%) al phase I	SN 5 (5.1%)	NS	
15:05 - 15.25Colon 20	Coffee	120	3 (2.5%)	3 (2.5%)	NS	
15:25 - 16:14 rostate 45	Immunohistochemical princip The technical test approach -		2(1.2%) al phase II	SN 2(1.2%)	NS	
16:15 - 17:06 tomach 45	Immunohistochemical classif			AVL 1(0.9%)	NS	
Salivary Gland 17.00 – 19.00	tumours Social arrangement (optional	56 I) – Keglespil	1(1.8%) (Skittles)	1(1.8%)	NS	
Thursday, Septembe	rcinoma of head and neck	38	0(0%)	0(0%)	NS	
Pancreatic adeno	carcinomas Optimization of antibodies, se	110	0(0%)	0(0%)	NS	
08:15 - 09:00 45 Breast	controls – breast tumours	34	0(0%)	$SN_{0(0\%)}$	NS	
09:00 - 09:45 45 NS: not significant	Immunohistochemical classif unknown primary tumour – p			MV NIH	Public Access Manuscript Manuscri	h 1.
09:50 - 10:10 20	Coffee				final edited form as: nohistochem Moi Morphol. 2010 March; 18(2): 142–149. doi:10.1097/PAI.0b013e318	81bdf4e7.
10:10 - 10:40 30	Optimization of antibodies, so			SN _{Compar}	rison of thyroid transcription factor-1 expression by	two
10:45 - 11:30 45	controls – unknown primary Immunohistochemical classif unknown primary tumour – p	ication of the		monocl MV tumors	onal antibodies in pulmonary and non-pulmonary pri	rimary
11:35 - 12:05 30	Optimization of antibodies, se		ocols and	Noble, Mur Department	ray B. Resnick, Ronald A. DeLellis, and Li J. Wang tof Pathology and Laboratory Medicine, Rhode Island Hospital and Brown Medividence, Rl.	

Diagnosis of metastasis to the lung

SN

ON

ON

MR

MB

Colon

Wednesday, September 20th

Program

17.00 - 19.00

09:30 - 10:00		Arrival, coffee
10:00 - 10:15	15	Welcome and introduction
10:15 - 11:00	45	Immunohistochemical principles:
		The technical test approach - pre-analytical phase I
11:05 - 11:50	45	Immunohistochem La Ales:
	N. N.	The technical test approach - pre-analytical phase II
12:00 - 12:45	45 🛝	Immunohistochemical/principles:
	100	The technical test approach - analytical phase I
12:45 - 13:30	45	Lunch
13:30 - 14:15	45	Immunohistochem@@inciples:
		The technical test approach - analytical phase
14:20 - 15:05	45/	Immunohistochem@X2rinciples:
		The technical test approach - post-analytical I
15:05 - 15.25	20	Coffee
15:25 - 16:10	45	Immunohistochemical principles:
		The technical test approach - post-analytical
16:15 - 17:00	45	Immunohistochem@4596ssification of breas
	2.75	The state of the s

Thursday, September 21st CD10

tumours

CNI
SN
511
MV
CN
SN
MV
I*I V
SN

Social arrangemen**t 63**ptional) – Keglespil (<u>Skittles)</u>

Diagnosis of metastasis to the lung

Wednesday, September 20th

Program

weanesaay, S	nber 20 th	1411	'රි	
09:30 - 10:00		Arrival, coffee		
10:00 - 10:15	15	Welcome and introduction	SN	
10:15 - 11:00	45	Immunohistochemical principles:	ON	
The control of the control of		The technical test approach – pre-analytical phase I	0	.
11:05 + 11:50	45	Immunohistochem	ON	Mamma
12:00 - 12:45	45	The technical test approach - pre-analytical phase II Immunohistochemical principles:		
12.00 12.75	為公司	The technical test approach - analytical phase I	MB	1000
12:45 - 13:30	45	Lunch		
13:30 - 14:15	45	Immunohistochem@k20inciples:	MP	
		The technical test approach - analytical phase II	1	
14:20 - 15:05	45/	Immunohistochem@XZrinciples:	SN	
15.05		The technical test approach - post-analytical phase I		
15:05 - 15.25 15:25 - 16:10	20 45	Coffee SAIDZ		48
13.23 - 10.10	43	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN	
16: 9 5 - 17:00	45	Immunohistochem@k596ssification of breast		
		tumours	AVL	7
17.00 - 19.00		Social arrangemen t (S ptional) – Keglespil (<u>Skit<mark>tles</mark>)</u>		
Thursday, Sept	embe	cD10		-
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	SN	
		controls - breast tumours		
09:00 - 09:45	45	Immunohistochemical glassification of the	MV	

08:15 - 09:00 45	Optimization of antibodies, selection, protocols and	SN
	controls - breast tumours	٠.٠
09:00 - 09:45 45	Immunohistochemical classification of the	MV
and the second	unknown primary ťumour – part I	
09:50 - 10:10 20	Coffee GATA3	
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and	SN
	controls – unknown primary tumours part I	SIN
10:45 - 11:30 45	Immunohistochemical classification of the	MV
	unknown primary tumour – part II	IYI V
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and	SN

Program

PRELIMINARY

Diagnosis of metastasis

to the lung

SN

ON

on Upper GI

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee
10:00 - 10:15	15	Welcome and introduction
10:15 - 11:00	45	Immunohistochemical principles:
		The technical test approach – pre-analytical phase I
11:05 - 11:50	45	Immunohistochem In A E Poles:
	A Park	The technical test approach pre-analytical phase II
12:00 - 12:45	45	Immunohistochemical principles:
	No.	The technical test approach - analytical phase
12:45 - 13:30	45	Lunch
13:30 - 14:15	45	Immunohistochem@kD@inciples:
		The technical test approach - analytical phase
14:20 - 15:05	45/	Immunohistochem@ax2ring.
		The technical test approach - post-analytical p
15:05 - 15.25	20 ~	Coffee SAIB2
15:25 - 16:10	45	Immunohistochemical principles:
	arrage asset	The technical test approach - post-analytical p
16:15 - 17:00	45	Immunohistochem@k5g/6ssification of breast
	Sec.	tumours
17.00 - 19.00		Social arrangement 63ptional) – Keglespil (Skittles)

Thursday, September 21st

CD10

	6 de la 10 a	<u> </u>	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	SN
		controls - breast tumours	0
09:00 - 09:45	45	Immunohistochemication of the	MV
THAT IS		unknown primary tumour – part I	
09:50 - 10:10		Coffee GATA3	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN
		controls – unknown primary tumours part I	JIV
10:45 - 11:30	45	Immunohistochemical classification of the	MV
		unknown primary tumour – part II	I*I V
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CN



Diagnosis of metastasis **PRELIMINARY Program**

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee		
10:00 - 10:15 1	.5	Welcome and introduction	SN	
10:15 - 11:00 4		Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON	
11:05 - 11 :50 4	I5	Immunohistochem In	ON	•
12:00 - 12:45 4	15 ()	The technical test approach – pre-analytical phase II Immunohistochemical principles: The technical test approach - analytical phase I	rothelial	carcinoma
12:45 - 13:30 4	15	Lunch		
13:30 - 14:15 / 4	5	Immunohistochem@k2@inciples:	MP	

The technical test approach - analytical phase II 14:20 - 15:05 Immunohistochem@X2rinciples: 45 The technical test approach - post-analytical phase SATB2 15:05 - 15.25 Coffee 20

15:25 - 16:10 Immunohistochemical principles: 45

The technical test approach - post-analytical phase II 16:15 - 17:00 45 Immunohistochem@6506ssification of breast

tumours

Social arrangement 63ptional) Keglespil (Skittle 17.00 - 19.00**CD10**

Thursday, September 21st

08:15 - 09:00 45 Optimization of antibodies, selection, protocols and SN controls - breast tumours 09:00 - 09:4545 Immunohistochemical classification of the MV unknown primary ťumour – part I

09:50 - 10:10 20 Coffee GATA3 <

10:10 - 10:40 30 Optimization of antibodies, selection, protocols and controls - unknown primary tumours part I

Immunohistochemical classification of the 10:45 - 11:30 45 unknown primary tumour - part II

11:35 - 12:05 **30** Optimization of antibodies, selection, protocols and MV

SN

SN

SN

AVL

to the lung



Diagnosis of metastasis PRELIMINARY to the lung

SN

MV

SN

Program

09:50 - 10:10

10:45 - 11:30

11:35 - 12:05

10:10 - 10:40

Wednesday, September 20th

20 Coffee

45

30

weariesday, s	Cptci	iibci 20	0
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase I	
11:05 - 11:50	45	Immunohistochem La A E Bles:	ON I II
12.00		The technical test approach – pre-analytical phas RIC	enai ceii carcinoma
12:00 - 12:45	45	Immunohistochemical principles:	MB
12:45 - 13:30	45	The technical test approach - analytical phase I Lunch	
13:30 - 14:15			
13.30 - 14.13	45	Immunohistochem@k2pinciples: The technical test approach - analytical phase	MB
14:20 - 15:05	45/	Immunohistochem Cax Principles:	
17.20 15.05	Constant of the		SN
15:05 - 15.25	20	The technical test approach - post-analytical place SATB2	
15:25 - 16:10	45	Immunohistochemicalyprinciples:	The Astronomy
		The technical test approach - post-analytical plant	SN
16: 2 5 - 17:00	45	Immunohistochem@k59l6ssification of breast	0.74
	100	tumours	AVL
17.00 - 19.00		ှ Social arrangemen ု (သ ptional) – Keglespil (<mark>Skittles</mark>	
Thursday, Sept	embe	er 21 st CD10	
08:15 - 09:00	45	Optimization of antibodies, selection, protoco	
		controls - breast tumours	SIV
09:00 - 09:45	45	Immunohistochemical classification of the	MV
THE STATE OF THE S		unknown primary tumour – part I	

GATA3

30 Optimization of antibodies, selection, protocols and

Optimization of antibodies, selection, protocols and

controls - unknown primary tumours part I

Immunohistochemical classification of the

unknown primary tumour - part II

Wednesday, September 20th

09:30 - 10:00	Arrival, coffee	
10:00 - 10:15 15	Welcome and introduction	SN
10:15 - 11:00 45	Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON
11:05 - 11:50 45		Prosta
12:00 - 12:45 45	Immunohistochemical principles: The technical test approach - analytical phase I	MB
12:45 - 13:30 45	Lunch	
13:30 - 14:15 / 45	The technical test approach - analytical phase II	мв
14:20 - 15:05 45	Immunohistochem Collegia Immunohistochem Colle	SN
15:05 - 15.25 20	Coffee SATB2	
15:25 - 16:10 45	Immunohistochemical principles The technical test approach - post-analytical phase II	SN
16: 1 5 - 17:00 45	Immunohistochem@k596ssification of breast tumours	AVL Rectum
17.00 - 19.00	Social arrangemen t (3 ptional) – Keglespil (<u>Skittles)</u>	
Thursday, Septemb	er 21 st CD10	artinia.
08:15 - 09:00 45	Optimization of antibodies, selection, protocols and controls - breast tumours	SN
09:00 - 09:45 45	Immunohistochemicatellassification of the unknown primary tumour – part I	MV
09:50 - 10:10 20		
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30 45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and	SN

Diagnosis of metastasis to the lung

ate

Program Diagnosis of metastasis

Wednesday, September 20th

11:35 - 12:05

30

09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach - pre-analytical phase I	
11:05 - 11:50	45	Immunohistochem Lander pre-analytical phase H	ndometrial cancer
· · · · · · · · · · · · · · · · · · ·	20.0	The technical test approach pre-analytical phase ##	igorricti iai caricci
12:00 - 12:45	45	Immunohistochemical principles:	MB
	010	The technical test approach - analytical phase	
12:45 - 13:30	۵ 45 ۰	Lunch	
13:30 - 14:15	45	Immunohistochem@k20 inciples:	MB
14 20 - 15 05		The technical test approach - analytical phase	
14:20 - 15:05	45/	Immunohistochem@X2rinciples:	SNOT MAKE THE
1000 1000		The technical test approach - post-analytical phase SATB2	
15:05 - 15.25 15:25 - 16:10	20 45	Coffee SAIDZ	
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach - post-analytical prince II	SN
16: 9 5 - 17:00	45	Immunohistochem@4596ssification of breast	A L
10.15 17.00		tumours	AVL
17.00 - 19.00		Social arrangemen t 63 ptional) – Keglespil (Skiltes)	
			The state of the s
Thursday, Sept	embe	r 21 CD10	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	
		controls - breast tumours	Yes
09:00 - 09:45	45	Immunohistochemical glassification of the unknown primary tumour – part I	N.
TANK		B. W. L. A. WARNING TOWN A.	
09:50 - 10:10	20	Coffee GATA3	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN
10.45 11.20	45	controls – unknown primary tumours part I	
10:45 - 11:30	45	Immunohistochemical classification of the	MV

unknown primary tumour - part II

Optimization of antibodies, selection, protocols and

to the lung

MV

SN

PRELIMINARY

Wednesday, September 20th

•		
09:30 - 10:00		Arrival, coffee
10:00 - 10:15	15	Welcome and introduction
10:15 - 11:00	45	Immunohistochemical principles:
1. F. C.		The technical test approach – pre-analytical phase I
11:05 - 11:50	45	Immunohistochem La La Alexandres:
		The technical test approach pre-analytical phase II
12:00 - 12:45	45	Immunohistochemical principles:
		The technical test approach - analytical phase
12:45 - 13:30	45	Lunch
13:30 - 14:15	45	Immunohistochem@@pinciples:
The second		The technical test approach - analytical phase
14:20 - 15:05	45/	Immunohistochem Cox Principles:
		The technical test approach - post-analytical place
15:05 - 15.25	20	Coffee
15:25 - 16:10	45	Immunohistochemicalyprinciples:
		The technical test approach - post-analytical place II
16:15 - 17:00	45	Immunohistochem@k596ssification of breast
	State Constate Constate	tumours
17.00 - 19.00		Social arrangemen ? 63 ptional) – Keglespil (<u>Saltes</u>
Thursday, S	entembe	21 st CD10
	XXXXXXXXX	CDIO

	100 to
08:15 - 09:00 4	Optimization of antibodies, selection, protoco
0/00/03/03/03/03/03/03/03/03/03/03/03/03	Optimization of antibodies, selection, protoco controls - breast tumours
09:00 - 09:45 4	5 Immunohistochemical classification of the
	unknown primary tumour – part I
09:50 - 10:10 2	o Coffee GATA3

10:10 – 10:40 **30** Optimization of antibodies, selection, protocols and

controls - unknown primary tumours part I Immunohistochemical classification of the

10:45 - 11:30 45 unknown primary tumour - part II

11:35 - 12:05 30 Optimization of antibodies, selection, protocols and

ON Ovarian cancer

Diagnosis of metastasis


to the lung

SN

SN

MV

SN



Diagnosis of metastasis PRELIMINARY to the lung

Wednesday, September 20th

Program

	•		
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase I	ON
11:05)+11:50	45	Immunohistochem La La Anta Poles:	Thyroid cancer
	Pa Pa	The technical test approach pre-analytical phase II	Pilly I Old Callee
12:00 - 12:45	45	Immunohistochemical principles:	MB
	No.	The technical test approach analytical phase I	MB
12:45 - 13:30	45	Lunch	
13:30 - 14:15	45	Immunohistochem@#20inciples:	MB
	and the	The technical test approach - analytical phase II	MD
14:20 - 15:05	45/	Immunohistochem@XZrinciples:	SN
		The technical test approach - post-analytical phase I	JIV.
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistochemical principles:	SN
Carlotte State Control of the Contro	4.72	The technical test approach - post-analytical phase II	L
16: 9 5 - 17:00	45	Immunohistochem@k5c/6ssification of breast	AVL 7
	and the	tumours	
17.00 - 19.00		Social arrangemen t (o ptional) – Keglespil (<u>skittles</u>)	
Thursday, Septe	mbe	er 21 st CD10	
08:15 - 09:00	45		ALTO CALL TO SERVICE OF THE SERVICE
08,13 - 09.00		Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45	45	TO THE PARTY OF TH	MV
09.00 03.43		Immunohistochemical glassification of the unknown primary tumour – part I	111
09:50 - 10:10	20	Coffee GATA3	A STATE OF THE PERSON NAMED IN COLUMN TO STATE OF THE PER
10:10 - 10:40	30	O/ II/ IS	
10.10-210.10		controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the	
10.15 11.50	75	unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	
11.55 12.05	30	opening and or anaboutes, selection, protocols and	SN



10:45 - 11:30

11:35 - 12:05

45

30

PRELIMINARY

Wednesday, September 20th

Mesothelioma

SN

MV

SN

Wednesday, sept	2000	
09:30 - 10:00	Arrival, coffee	
10:00 - 10:15 15	Welcome and introduction	SN
10:15 - 11:00 45	A PARTICULAR PROPERTY AND A PARTICULAR PROPE	ON
The second second second	The technical test approach – pre-analytical phase I	
11:05 - 11 :50 45		ON
	The technical test approach – pre-analytical phase II	
12:00 - 12:45 45		
	The technical test approach - analytical phase	
12:45 - 13:30 45	VVI I	
13:30 - 14:15 / 45	ALT TO BE STOLET U.S. TO STOLET STOLET	M
	The technical test a p2040h - analytical phase	
14:20 - 15:05 45	d State Section 2015 and the s	
	The technical test approach - post-analytical pase	S A ROOM
15:05 - 15.25 20	VIII	
15:25 – 16:10 45		
16: 9 5 - 17:00 45	The technical test a 如何 - post-analytical phase	
16: 15 - 17:00 45		
17 00 10 00	tumours	
17.00 - 19.00	Social arrangement (optional) – Keglespil (<mark>Skithes</mark>)	
Thursday, Septemb	per 21 st	
08:15 - 09:00 45	Optimization of antibodies, selection, protoco	
	controls - breast tumours	
09:00 - 09:45 45	Immunohistochemical classification of the	MV
Silf Alban	unknown primary tumour – part I	
09:50 - 10:10 20	TOTAL MANAGEMENT OF THE PROPERTY OF THE PROPER	
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and	SN
		עוכ

controls - unknown primary tumours part I

Optimization of antibodies, selection, protocols and

Immunohistochemical classification of the


unknown primary tumour – part II



PRELIMINARY

Wednesday, September 20th

• •	•		
09:30 <u>-</u> 10:00 10:00 - 10:00	/ धू	Arrival, coffee Teamco Immunohistochemical principles:	nference
10:15 - 11:00	45	Immunohistochemical principles: The technical test approach — pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
12:45 - 13:30	45	Lunch	
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	МВ
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN
15:05 - 15.25	20	Coffee	100 March 1997
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN
16:15 - 17:00	45	Immer ohistochemical classification of breast	AVL
17.00 - 19.00		cial arrangement (optional <mark>) – Keglespil (Skittles)</mark>	
Thursday, Sep	5015	THE RESERVE TO THE PARTY OF THE	The same
08:15 - 09:00	-	Optimization of antibodies, selection, protocol and controls – breast tumours	SN
09:00 - 09:45	45	Immunchistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	
		controls – unknown primary tumours part I	SIV
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN





Program		PRELIMINARY		
Wednesda	y, S <u>ep</u> tei	mber 20 th		
09:30 - 10:00		Arrival, coffee		
10:00 - 10:15	15	Welcome and introduction	SN	
10:15 - 11:00	45	Immunohistochemical principles:	ON	
	50	The technical test approach – pre-analytical phase I	ON	_
11:05 - 11:50	45	Immunohistochemical principles:	ON	
		The technical test approach – pre-analytical phase II	ON _	
12:00 - 12:45	45	Immunohistochemical principles:	MB	
	40	The technical test approach - analytical phase I	1710	
12:45 - 13:30	45	Lunch		
13:30 - 14:15	45	Immunohistochemical principles:	МВ	
14-20 15-05	% ₃₀	The technical test approach - analytical phase II		
14:20 - 15:05	³⁰ 45	Immunohistochemical principles:	SN	
15:05 - 15.25	20	The technical test approach - post-analytical phase I Coffee		
15:25 - 16:10		Immunohistochemical principles:		
13.23 - 10.10	20 45	The technical test approach - post-analytical phase II	SN	—— 0/la
16:15 - 17:00	45	Immunohistochemical classification of breast		lb
10113 17100]	tumours	AVL	lla III
17.00 - 19.00	10	Social arrangement (optional) - Keglespil (Skittles)		■ IIb — ■ IIIa
Thursday C	, ,			■ IIIa ■ IIIb
Thursday, S	-			IV
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	SN	Uoplyst
	0 1	controls - breast tumours		
09:00 - 09:45	45 ₂	20dg_muhahistochemical sheatificationoffsthe 2016	^M ∕2017	
00.50 10.10	20	unknown primary tumour – part I Coffee		
09:50 - 10:10	20			
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – wkbay simark tulid spart of SIS	SN	
10:45 - 11:30	45	Immunohistochemical classification of the		
10.73 - 11.30	73	unknown primary tumour – part II	MV	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and		
11.55 - 12.05	<u> </u>	opullization of antibodies, selection, protocols and	SN	



11:35 - 12:05

30

Program wednesday, Septe PatΩ anatomical specimen

WCuii	CSua	y, septen	iber 2001 10. CO 1111 COIL Of COIL		
09:30 -	10:00		Arrival, coffee		
10:00 -	10:15	15	Welcome and introduction	SN	
10:15 -	11:00	45	Immunohistochemical principles:	L 201	
			The technical test approach – pre-analytical phase	rmingv	
11:05 -	11:50	Histology 45	Immunohistochemical principles:	tology	
NAME OF THE PARTY		Пізсоюду	The technical test approach – pre-analytical phase II	ON S	
:00 -	12:45	45	Immunohistochemical principles:	MD	
		Civation	The technical test approach - analytical phase I	MB	•
12:45 -	13/30	Fixatiqg	Lunch		
13:30	14:15	Dehvolusation	Olfnmunohistochemical principles:	Smear preparation	
		•	- · · · · · · · · · · · · · · · · · · ·	Spile at preparation	
14:20 -	1/5:05	Parangem	The technical test approach Panalytical phase II in municiples:	CN	AKH KC01-5229 A GIEMSA
D > 100		Microtom	y The technical test approach - post-analytical phase I	SN	
15:05 -	15.25	20	Coffee		1
15:25	16:10	45	Immunohistochemical principles:	CNI	100
			The technical test approach - post-analytical phase II	SN	
16:15 -	17:00	45	Immunohistochemical classification of breast	AVL	
PA	Marie (Mar		tumours	AVL	
17.00 -	19.00		Social arrangement (optional) - Keglespil (Skittles)		
Thurs	day 6	Septembei		1	
			VIJAAIIZACIOI		
08:15 -	09:00	45	Optimization of antibodies, selection, protocols and	SN	
			controls – breast tumours		
09:00 -	09:45	45	Immunohistochem/cat classification of the	MV	
			unknown primary woold bart [18]		
09:50 -		20	Coffee		
10:10 -	10:40	30	Optimization of antibodies, selection, protocols and	SN	
			controls – unknown primary tumours part I		
10:45 -	11:30	45	Immunohistochemical classification of the	MV	
			unknown primary tumour – part II	1 1 0	

Optimization of antibodies, selection, protocols and



11:35 - 12:05

30


Program		PRELIMINARY		
Wednesday, 9	Septen	nber 20 th		
09:30 - 10:00		Arrival, coffee		
10:00 - 10:15	15	Welcome and introduction	SN	
10:15 - 11:00	45	Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON	
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON	
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	MB	
12:45 - 13:30	45	Lunch		
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	МВ	
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN	10000
15:05 - 15.25	20	Coffee	3	6 200 4 901
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN	
16:15 - 17:00	45	Immunohistochemical classification of breast tumours	AVL	
17.00 - 19.00		Social arrangement (optional) - Keglespil (Skittles)	34 700	
Thursday, Sep	tembe			0
08:15 - 09:00 Adenocarcino		Optimization of antibodies, selection, patential controlling transfer meuroendo	SN Crine carc.	Small cell carcinoma
< 09:00 − 09:45	45	Immunohistochemical classification of the	MV	
Non-Small	Ge	unknown primary tumour - part I		
10:10 - 10:40	30 / N I	Optimization of antibodies, selection, protocols and Controls—unknown primary tumours part I	SN	
10:45 - 11:30	(45N	Immunonistochemical classification of the unknown primary tumour – part II	MV	
		anknown primary turnour part II		

Optimization of antibodies, selection, protocols and



PRELIMINARY

Wednesday, Septe	ember 20 th	
09:	Arrival, coffee	
		SN
10:15 - 11:00 45	Immunohistochemical principles: The technical test approach pre analytical phase I	ON
11:05 - 11:50 45	Immunohistochemical principles: The technical test approach - pre-analytical phase II	ON
12:00 - 12:45 45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
12:45 - 13:30 45	Lunch	
13:30 - 14:15 45	Immunohistochemical principles: The technical test approach - analytical phase II	МВ
14:20 - 15:05 45		SN
15:05 - 15.25 20	Coffee	
15:25 - 16:10 45	Immunohistochemical principles:	C.N.
	The technical test approach - post-analytical phase II	SN
16 :15 – 17:00 45	Immunohistochemical classification of breast	AVL
	tumours	/ .
17.00 - 19.00	Social arrangement (optional) – Keglespil (<u>Skittles</u>)	
Thursday, Septemb	er 21 st	
08:15 - 09:00 45	Optimization of the cols and	SN
09:00 - 09:45 45	controls – breast tumours	N/1\ /
09:0 0 - 09: 45 45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10 20	Coffee	
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and	
	controls – unknown primary tumours part I	SN
10:45 - 11:30 45	Immunohistochemical classification of the	MV
	unknown primary tumour – part II	1*1 V
11:35 – 12:05 30	Optimization of antibodies, selection, protocols and	SN



Cellblock

Immunocytologi



14:20 - 15:0

15:05 - 15.25

15:25 - 16:10

16:15 - 17:00

17.00 - 19.00

11:35 - 12:05

PRELIMINARY

Wednesday, September 20th

09:00 - 10:00	Arrival, coffee	
09: 0 y 10:00 logy 15	Welcome and introduction	SN
10:15 - 11:00 45	Immunohistochemical principles:	ON-
	The technical test approach – pre-analytical phase 1	WY.
11:05 – 11:50 45	Immunohistochemical principles:	ON
	The technical test approach – pre-analytical phase 1	II ON
12:00 - 12:45 45	Immunohistochemical principles:	МВ
	The technical test approach variation phase I	
12:45 - 13:30 DAB 45 13:30 - 14:15 DAB45	Lunch	V2V4 - 18
13:30 - 14:15 45	Immunohistochemical principles:	MR

The technical test approach - analytical phase I

Immunohistochemical principles:

The technical test approach - post-analytical phase I

Coffee Sekundært antistof

Coffee

Immunohistochemical principles:
The technical test approach - post-analytical phase II

Immunohistochemical classification of breast

Optimization of antibodies, selection, protocols and

tumours

Social arrangement (optional) – Keglespil (Skittl Cellekerne

Thursday, September 21st

30


08:15 - 09:00	45	optimization of antibodies, selection, protocols and controls – breast tumours
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I
09:50 - 10:10	20	Coffee
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II

SN


d tofl-CK7

MV

SN



Patient selection in lung cancer: Evolution over time





P	ro	a	ra	m
-	. •	_		

PRELIMINARY Positive Histology

Step 1

Wednesday, September 20th

rreallesady, se	PCC.	
09:30 - 10:00		Arrival, coffee Positive Cytology NE morphology, small cells
10:00 - 10:15	15	Welcome and introduction
10:15 - 11:00	45	Immunohistochemical principles: The technical test approach – pre-analytical phase I
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I
12:45 - 13:30	45	Lunch prominent eccentrical No clear SQCC or
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II MB
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I > 2
15:05 - 15.25	20	Coffee Apply ancillary panel of
15:25 - 16:10	45	Immunohistochemica Priciples: The technical test approach - post-analytical phase II
16:15 - 17:00	45	Immunohistochemical classification of breast tumours
17.00 - 19.00		Social arrangement (optional) – Keglespil (<u>Skittles</u>)
	_	3000 marker - 3000 marker -

Thursday, September 21st

<i>,</i> , ,			
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the NSCLC, unknown primary tumour – part I	NOS
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodiscolection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical Classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN

SQCC




NSCLC, NOS

possible adenosquamous ca.



PRELIMINARY


Wednesday, September 20th






PRELIMINARY

Wednesday, September 20th





Wednesday



STATE OF THE ART CONCISE REVIEW 30





09

PRELIMINARY

Wednesday, September 20th

Danish Lung Cancer Group (DLCG)





Thursday, September

Lungecancer – Patologi

08:15 - 09:00 45 Optimization of antibodies, selection, protocols and SN controls - breast tumours

46. OReflextest af de obligatoriske handebrersbisetkorettiges ved den primære unknown primary tumour – part I og:5 diagnostik af nødenstående grupper. (A)

10:10 - 50:42GFR, ALK, PROSINITATION FROM PROPRIENT IN THE STATE AND ACTION OF LONG TO THE STATE OF THE STATE

MV


knke-smacellede karcinomer Optimization of antibodies, selection, protocols and

SN



PRE

Wednesday, September 20th





PRELIMINARY

Wednesday, September 20th

		-D		
09:30 - 10:00	H(-1	Prival, coffee		
10:00 - 10:15	-15	Welcome and introduction	SN	
10:15 - 11:00	45	Immunohistochemical principles:	ON	_
		The technical test approach - pre-analytical phase I	ON	TG α Interleukin-8
11:05 - 11:50	45	Immunohistochemical principles:		bFGF
		The technical test approach - pre-analytical phase II	ON	VEGF
12:00 - 12:45	45	Immunohistochemical principles:	MD	
		The rechnical test approach - analytical phase I	MB	
12:45 - 13:30	45	Lunchn		
13:30 - 14:15	45			
		The technical test approach - analytical phase II	MB	3
14:20 - 15:05	45	Immunohistochemical principles:	RAS	
		The technical test approach - post-analytical phase I	SN	
15:05 - 15.25	20	Coffee	RAF	
15:25 - 16:10	45	Immunohistochemical principles:		
		The technical test approach - post-analytical phase II	SN	
16:15 - 17:00	45	Immunohistochemical classification of breast		
		tumours	AVL	
17.00 - 19.00		Social arrangement (optional) - Keglespil (Skittles)		
Thursday Cont	b -		2/	
Thursday, Sept	embe			757000000000000000000000000000000000000
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	SN	
	Plasma	controls – breast tumours		-Nucleus
09:00 - 09:45	r 45 bran	 Immunohistochemical classification of the 	MV	
		unknown primary tumour – part I		
09:50 - 10:10	20	Coffee		
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN	
		controls - unknown primary tumours part I	211	Cutoplases
10:45 - 11:30	45	Immunohistochemical classification of the	MV	Cytoplasm
		unknown primary tumour – part II	I'I V	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN	



PRELIMINARY

Wednesday, September 20th

• •	•		
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome band introduction Tyrosine kinase	S Nophosphorylation
10:15 - 11:00	45	Immunohistochemical principles:	ON
	Ex	on The technical test approach in pre-analytical phase I 22	_24 ON 28
11:05 - 11:50	45	Immunohistochemical principles:	、 ON
	with o	tions associated hnical test approach – pre-analytical phase II	ON
12:00 - 12:45	45	- Immunohistochemical principles' p770 N771 (ins NPG)	MB
		The technical test approach - analytic 3770 1777 (int SVQ)	MD
12:45 - 13:30	45	-1 unch V769L	
13:30 - 14:15	45	Immunohistochemical principles:	MB in
	989	The recrimed test approach analytical phase II	875 4 IAID
14:20 - 15:05	45	Immunohistochemical principles: Exon 20	Exon 21 S Nictivation loop
		The technical test approach - post-analytical phase I	
15:05 – 15.25	20	G<u>T</u>96ffee ΔΕ 746-A750 V765A T783A	L858R (40–45%) N826S
15:25 - 16:10	45	ginamunohistochemical-principles: (<1%)	A839T S N 846R
		Notice technical test approach (Notice) phase II	L861Q
16:15 - 17:00	45	E7Deximunohistoche mical of breast	G863D AVL _(40–45%)
\	L	tumours AL747-A750 (ins P)	/ (* - (40–45%)
17.00 - 19.00 \		Social arrangement (5) (5) (ns 1/3) – Keglespil (<u>Skittles</u>)	
Thursday, Septe	embe	11777 0750	
08:15 - 09:00	Muta With	drug sensitivity of antibodies, selection, protocols and	
08.13 - 09.00	7	controls – breast turnous sins s)	SN
09:00 - 09:45	45	Immunohistochemical-classification of the	M
09.00 09.49	75	unknown primary tumo(1%)- part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Ontimization of antibodies selection protocoleand	_
10.10 10.10		Optimization of antibodies, selection, protocoloring controls – ualdioaaat Maires t	K SN
10:45 - 11:30	45	Immunohistochemical classification of the	_
100 11.00		unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CNI
		, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	SN




PRELIMINARY

↑ TAGRISSO® 80 mg

osimertinib

SN

Wednesday, September 20th





PRELIMINARY

Wednesday, S	Septer	mber 20th Contents lists available at ScienceDirect
09:30 - 10:00	-	Arrival, coffee Lung Cancer
10:00 - 10:15	15	Welcome and introduction momepage: www.elsevier.com/locate/lungcan SN
10:15 - 11:00	45	Immunohistochemical principles:
		The technical test approach - pre-analytical phase I
11:05 - 11:50	45	Immove FGER mutation specific antibodies for lung adenocarcinoma: Immove FGER mutation specific antibodies for lung adenocarcinoma:
10.00 10.15		The flechnical test approach — pre-analytical phase II Example 19 and an L858R mutation in exon 21 by immunohistochemistry Immunohistochemical principles: MB
12:00 - 12:45	45	Immunohistochemical principles: The AnaNa Second Park Park P. J. Yan Ling P. C. Ping Liu Sun e. C. Hwojin Kim e. C. MB
12:45 - 13:30	45	Then the central transfer of the second state of the second secon
13:30 - 14:15	45 45	Lunghtment of Pathology, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Cyeonggi 463-707, Republic of Korea Department of Pathology, Kyungpook National University College of Medicine, 680 Gukchaebosang-ro, Jung-gu, Daegu 700-842, Republic of Korea
13:30 - 14:13	45	In Partition of Pathology, Kyungpook National University Building Hospital, 300 dunit-long Buildings (a) Department of Pathology, Kyungpook National University College of Medicine, 680 Gukchaebosang-ro, Jung-gu, Daegu 700-842, Republic of Korea Implication of Pathology, Kyungpook National University Englang Hospital, 300 Gumi-dong, Bundang-ro, Jung-gu, Daegu 700-842, Republic of Korea Implication of National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi 463 MB Bepublic of The Recent Control of Pathology (Control of Pathology) The Recent Control of Pathology, Kyungpook National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi 463 MB Bepublic of Control of Pathology (Control of Pathology) The Recent Control of Pathology, Kyungpook National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi 463 MB Bepublic of Control of Pathology (Control of Pathology) The Recent Control of Pathology, Kyungpook National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi 463 MB Bepublic of Control of Pathology (Control of Pathology) The Recent Control of Pathology, Kyungpook National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi 463 MB Bepublic of Control of Pathology (Control of Pathology) The Recent Control of Pathology
14:20 - 15:05	45	Immilhonistochemical brinciples:
11120 13103		The technical test approach - post-analytical phase I 22-24 28
15:05 - 15.25	20	Coffee Mutations associated Mutations associated
15:25 - 16:10	45	1mmunopistochemical principles: 1790M (50%)*
		I ne technical test approach - post-analytical phase d
16:15 - 17:00	45	Immunohistochemical classification of breast 771 (ins G), N771T AVL
		tumours
17.00 - 19.00		Social arrangement (optional) Keglespil (Skittles) 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Thursday, Sept	tembe	
08:15 - 09:00	45	Optimization of antibodies (40–45%) N8265
		controls (51%) reast tumours 1746 T751 (ins. A / 1) (<1%) A839T
09:00 - 09:45	45	Immunohistochemical classification of the MV G861Q G863D
		unknown tumour LZ47 by 29 (40–45%)
09:50 - 10:10	20	Coffee (5%) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (1517) (151
10:10 - 10:40	30	Optimization of antibodies 74selection, protocols and
10.45	a –	CONTROLS IN SUNKNOWN PRIMARY TUMBOURS PART I
10:45 - 11:30	45	Immunohistochemical classification of the
11:35 - 12:05	20	unknown primary tumoursszpart II Ontimization of antibodies, c45% bring protocols and
11:35 - 12:05	30	Optimization of antibodies, sélection, protocols and SN



10:45 - 11:30

11:35 - 12:05

45

30

Program		PRELIMINARY			
_			•	3+	
Wednesday,	Septer	nber 20 th			
09:30 - 10:00		Arrival, coffee			
10:00 - 10:15	15	Welcome and introduction	SN SN		E746-A750
10:15 - 11:00	45	Immunohistochemical principles: The technical test approach – pre-analytical phase	I ON		del-specific AB SPI
11:05 - 11:50	45 ^A	Immunohistochemical principles: C The technical test approach – pre-analytical phase	D ON		
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	MB		E746-A750
12:45 - 13:30	45	Lunch			del-specific AB SPI
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	MB		
14:20 - 15:05	45	Immunohistochemical principles:	CN		
Table 2 15:05 - 15.25 ^{Diagno}	2 ostic power of n	The technical test approach - post-analytical phase nutation specific antibodies comparing with EGFR mutational status.	I SN		
15:25 - 16:10 Muta	ation-sp acifi c ar	ntibinimunohistochemicals principles: Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
Anti-	-EGFR E746_A75	50 作he technicaf 社会化 approach - post-analytical phase Score 1 as positive Immunohistoshemical is lassification of breast	II SN		
16:15 - 17:00	45	>Score 1 as positive 94.1% Immunohistochemical: Glassification of breast	96.1%	80.0% 92.3%	99.0% 95.3%
10113 17100		tumours ≥Score 3 as positive 29.4%	99 4%/ L	100.0%	89.6%
17.00 - 19.00		Social arrangement (Optional) - Keglespil (Skittle	es) _{96.6%}	85.0%	86.0%
		Score 2 as positive 40.2%	99.4%	96.2%	82.7%
Thursday, Se		21 Score 3 as positive 16.1%	100.0%	100.0%	77.4%
08:15 - 09:00 Anti-	-EGFR L858R 45	Optimization of antibodies, selection protocols a	nd 50.0% 89.7%	30.7%	97.0%
		controls – breast tempeturs 80.4%		64.9% 100.0%	95.1% 87.8%
09:00 - 09:45	iations: PPV, po	Immunohistochemical classification of the sitive predictive value: NPV pegative predictive value: NPV pegative predictive value: Unknown primary tumour – part I	100.0% MV	100,000	
09:50 - 10:10	20	Coffee			Contents lists available at ScienceDirect
10:10 - 10:40	30	Optimization of antibodies, selection, protocols a	nd _{CN}	ELSEVIER journal	homepage: www.elsevier.com/locate/lungcan
		controls – unknown primary tumours part I	SN	Novel EGFR mutation-spec Highly specific but not sen	ific antibodies for lung adenocarcinoma:
				40 1 10500	and the second second second

Immunohistochemical classification of the

Optimization of antibodies, selection, protocols and

unknown primary tumour – part II

exon 19 and an L858R mutation in exon 21 by immunohistochemistry

MV



11:35 - 12:05

30

Program

9		
Wednesday, S	Septe	mber 20th Algorithm
09:30 - 10:00		Arrival, coffee
10:00 - 10:15	15	Welcome and introduction SN
10:15 - 11:00	45	Immunohistochemical principles carcinomas The technical test approach - pre-analytical phase I
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II ON
12:00 - 12:45	45	Immunohistochemical principles: The technical tes Cappodintations posific IHC MB
12:45 - 13:30	45	Lunch
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II
14:20 - 15:05	45	Immunohistochemical principles: The technikeCtesttopp roach - post-analytical phase IIHE 13+
15:05 - 15.25	20	Coffee
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach - post-analytical phase II
16:15 - 17:00	45	Immunohistochemical dessification of breastGFR mutation +
17.00 - 19.00		Soc tora Factore Remultations - Keglespil (<u>Skittles</u>)
Thursday, Sep	tembe	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols FGFRTKIS controls - breast tumours
09:00 - 09:45	45	Immunohistocherical elassification of the MV unknown primary tumour – part I
09:50 - 10:10	20	Coffee Lung Cancer
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls Full Property tumours part I SN Remutation-specific antibodies for lung adenocarcinoma: cific but not sensitive detection of an E746.4750 deletion in
10:45 - 11:30	45	Immunohistochemical classification of the An As Second, Tac-In Park My yan Jines, Ping-Li Sun M, Hyojin Kim M. Hyon Charles In-Rene Church M. Hyon Church M

unknown primary tumour – part II

Optimization of antibodies, selection, protocols and

An Na Seo $^{\lambda,b,1}$, Tae-In Park h,1 , Yan Jin $^{\lambda,c}$, Ping-Li Sun a,c , Hyojin Kim $^{\lambda,c}$, Hyun Chang d , Jin-Haeng Chung $^{\lambda,c,*}$


MV



PRELIMINARY

Wednesday, September 20th

	- -	•				
	09:30 - 10:00		Arrival, coffee			
	10:00 - 10:15	15	Welcome and introduction	SN		
	10:15 - 11:00	45	Immunohistochemical principles:	ZONT.		
			The technical test approach – pre-analytical phase	ON		
	11:05 - 11:50	45	Immunohistochemical principles:	ON		
			The technical test approach – pre-analytical phase II	OIV		
	12:00 - 12:45	45	Immurchistochemical principles:	MB		
			The technical test approach - analytical phase I	IND		
	12:45 - 13:30	45	Lunch			
	13:30 - 14:15	45	Imm <mark>unp</mark> histochemical principles:	MB		
			The technical test approach - analytical phase II		1	
	14:20 - 15:05	45	Immunohistochemical principles:	SN		
			The technical test approach - post-analytical phase I		75.5	
	15:05 - 15.25	20	Coffee $NA(template) \rightarrow P(t)$	R		-
1	15:25 - 16:10	45	Immunohistochemical/principles:	SN	4	
W			The technical test approach - post-analytical phase II			
	16/15 - 17:00	45	Immunobistochemical classification of breast	AVL	1000	
~	17.00		tumours			
	17.00 - 19.00		Social arrangement (optional) – Keglespil (Skilles)			



Thursday, September 21st

Titul Budy/ Beptell			
1834 to 886910n	5	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45 4	5	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10 2	0	Coffee	
10:10 - 10:40 3	0	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30 4	5	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05 3	0	Optimization of antibodies, selection, protocols and	CN



11:35 - 12:05

30

PRELIMINARY

Wednesday, September 20th

O9:30 - 10:00 10:00 - 10:15 15 Welcome and introduction 10:15 - 11:00 45 Immunohistochemical principles: The technical test approach pre-analytical phase I 11:05 - 11:50 45 Immunohistochemical principles: The technical test approach - pre-analytical phase II 12:00 - 12:45 45 Immunohistochemical principles: The technical test approach - analytical phase I 12:45 - 13:30 45 Lunch 13:30 - 14:15 45 Immunohistochemical principles: The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: The technical test approach - analytical phase II 15:05 - 15:05 20 Coffee Thirties approach - post-analytical phase I 15:05 - 15:05 20 Coffee Thirties approach - post-analytical phase II Lase Detector
10:00 – 10:15 10:15 – 11:00 45 Immunohistochemical principles: The technical test approach pre-analytical phase I 11:05 – 11:50 45 Immunohistochemical principles: The technical test approach – pre-analytical phase II 12:00 – 12:45 45 Immunohistochemical principles: The technical test approach – analytical phase I 12:45 – 13:30 45 Lunch 13:30 – 14:15 45 Immunohistochemical principles: The technical test approach – analytical phase II 14:20 – 15:05 45 Immunohistochemical principles: The technical test approach – analytical phase II 15:05 – 15:05 46 Immunohistochemical principles: The technical test approach – post-analytical phase II 15:05 – 15:05 20 Coffee ***** **The technical test approach – post-analytical phase II **The technical test appro
The technical test approach pre-analytical phase I Immunohistochemical principles: The technical test approach – pre-analytical phase II 12:00 – 12:45 45 Immunohistochemical principles: The technical test approach – analytical phase I 12:45 – 13:30 45 Lunch 13:30 – 14:15 45 Immunohistochemical principles: The technical test approach – analytical phase II 14:20 – 15:05 45 Immunohistochemical principles: The technical test approach – analytical phase II 15:05 – 18:05 20 Coffee Transport
11:05 – 11:50 45 Immunohistochemical principles: The technical test approach – pre-analytical phase II 12:00 – 12:45 45 Immunohistochemical principles: The technical test approach – analytical phase II 12:45 – 13:30 13:30 – 14:15 45 Immunohistochemical principles: The technical test approach – analytical phase II 14:20 – 15:05 45 Immunohistochemical principles: The technical test approach – analytical phase II 15:05 – 15:05 46 Immunohistochemical principles: The technical test approach – post-analytical phase II 15:05 – 15:05 20 Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee Coffee
11:05 – 11:50 45 Immunohistochemical principles: date approach – pre-analytical phase II 12:00 – 12:45 45 Immunohistochemical principles: The technical test approach – analytical phase I 12:45 – 13:30 13:30 – 14:15 45 Immunohistochemical principles: The technical test approach – analytical phase II 14:20 – 15:05 45 Immunohistochemical principles: The technical test approach – analytical phase II 15:05 – 15:05 46 Immunohistochemical principles: The technical test approach – post-analytical phase I 15:05 – 15:05 47 Immunohistochemical principles: The technical test approach – prost-analytical phase I 15:05 – 15:05 48 Immunohistochemical principles: The technical test approach – prost-analytical phase I 15:05 – 15:05
The technical test approach – pre-analytical phase II 12:00 – 12:45 45
The technical test approach - analytical phase I 12:45 - 13:30 45
12:45 – 13:30 13:30 – 14:15 45 Immunohistochemical fest approach - analytical phase I 14:20 – 15:05 45 Immunohistochemical fest approach - analytical phase II 14:20 – 15:05 45 Immunohistochemical fest approach - analytical phase II 15:05 – 15:05 20 Coffee Detector The technical test approach - post-analytical phase I Laser Detector
13:30 – 14:15 45
The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: The technical test approach - post-analytical phase I 15:05 - 12.25 20 Coffee - Indicated test approach - post-analytical phase I Laser Detector
14:20 – 15:05 45 Immunohistochemical principles: The technical test approach - analytical phase II 15:05 – 15.25 20 Coffee Total Principles: Detector
The technical test approach - post-analytical phase I 15:05 - 15.25 20 Coffee Transport - Detector
15:05 – 15.25 20 Coffee Translatest approach - post-analytical phase I Detector
15.25 46.10 AF Transport bists also assists I with a fall and
15:25 – 16:10 45 Immunohistochemical principles:
The technical test approach - post-analytical phase II
16:25 – 17:00 45 Immunohistochemical classification of breast
Analysis tumours
17.00 - 19.00 Social arrangement (optional) - Keglespil (Skittles)
Thursday, September 21st September 2
- MANAGAMM
08:15 – 09:20 45 Optimization of antibodies, selection, protocols and sn
09:00 – 09:45 45 Immunohistochemical classification of the MV
unknown primary tumour – part I
09:50 - 10:10 20 <i>Coffee</i>
10:10 - 10:40 30 Ontimization of antibodies selection protocols and
controls – unknown primary tumours part I
10.45 - 11.30 45 Immunohistochemical classification of the
unknown primary tumour – part II

Optimization of antibodies, selection, protocols and



PRELIMINARY bassed test

Wednesday, September 20th

10:00 – 10:15 15 Welcome and introduction SN Loop	
Dischar Seguence	
10:15 – 11:00 45 Immunohistochemical principles:	
The technical test approach – pre-analytical phase I	
11:05 – 11:50 45 Immunohistochemical principles lem	er
The technical test approach - pre-analytical phase II	
12.00 12.45 AE Immunohistochomical principles	
The technical test approach - analytical phase I PCR Primer PCR Primer	
12:45 – 13:30 45 Lunch 5' Reporter Newly Synt	
12.20 14.15 AF Immunohistochomical principles	1
The technical test approach - analytical phase II	
14:20 – 15:05 Immunohistochemical principles: 1. Quenching of the fluorescence 2. Emission of the fluorescence	e
14:20 – 15:05 Immunohistochemical principles: 1. Quenching of the fluorescence SN The technical test approach - post-analytical phase I	500
15:05 – 15.25 20 Coffee	
15:25 – 16:10 45 Immunohistochemical principles:	
I ho tochnical toct approached noct applytical phace II	•
16:15 = 17:00 45 Immunohistochemical classification of breast mutationspecific prime	
tumours	
17.00 – 19.00 Social arrangement (optional) Keglespil (Skittles)	


Thursday, September 21st

08 15 109:00	45	Optimization of antibodies, rejection, protocols and	SN
09:00/-/09:45	45	controls – breast tumours Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10 10:10 - 10:40	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN

Scientific Advances in Lung Cancer 2015

Journal of Thoracic Oncology Vol. 11 No. 5: 613-638







PRELIMINARY

Wednesday, September 20th

09:30 - 10:00	Arrival, coffee		
	5 Welcome and intr	roduction	SN
10:15 - 11:00 4			314
10.15 - 11.00 -		approach – pre-analytical phase I	ON Cell survival
11:05 - 11:50	5 Immunohistocher		
11.05		approach – pre-analytical phase II	ON _{S6K}
12:00 - 12:454			mTOR
		approach - analytical phase IAKT	MB
12:45 -\13:30 _k 4	53 LunctEML4/ALK	1	
/ 16-13	5 Immunohistocher	mical-principles:	
	The technical test	approach - analytical phase I	Proliferation
14:20 - 15:05	5 Immunohistocher		CNI
	The technical test	approach versiost-analytical phase I	$SN \longrightarrow RAS \longrightarrow MEK \longrightarrow ErK$
15:05 – 15.25 2	0 Coffee		
15:25 – 16:10 4	5 Immunohistocher	mical principles:	SNPLC-y
	The technical test	approach - post-analytical phase II	SINPLC-Y
16:15 – 17:00 [] 4	5 Immunohistocher	nical classification of breast protein	Δ\/I
	tumours		AV
17.00 – 19.00	Social arrangeme	nt (optional) – Keglespil (<u>Skittles</u>)	
Thursday, Septem	ber 21 st		IP ₃
08:15 - 09:00 4	5 Optimization of a	tibodies, selection, protocols and	2011 American Association for Cancer Research
	controls - breast	TUITO WIGGular Pathways	AR
09:00 - 09:45 4	5 Immunohistocher	nical classification of the	MV
	unknown primary	tumour – part I	
09:50 - 10:10 2	O Coffee		
10:10 - 10:40 3	Optimization of ar	ntibodies, selection, protocols and	SN
		vn primary tumours part I	JIV
10:45 - 11:30 4	5 Immunohistocher	nical classification of the	MV
	unknown primary	•	1-1 V
11:35 – 12:05 3	Optimization of an	ntibodies, selection, protocols and	SN



PRELIMINARY

Wednesday, September 20th

09:50 Massacousetto Medical Society 20

10:10 - 10:40

10:45 - 11:30

11:35 - 12:05

- -	_		
09:30 - 10:00		Arrival, coffee	Inversion
10:00 - 10:15	15	Welcome and introduction	■SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase I	. CCR Molecular Pathwa
12:00 - 12:45	45	Immunohistochemical principles:	МВ
		The technical test approach - analytical phase I	טויו
12:45 - 13:30	45	Lunch	
13:30 - 14:15	45	Immunohistochemical principles:	МВ
60 ¬		The technical test approach - analytical phase II	ITID
14:20 - 15:05	45	Immunohistochemical principles: ■Disease progression	<u> </u>
- 40 T		The technical test approach - post-analytical phase I	514
15:05 - 25.225	20	Coffee Partial response Complete response	
15:25 - 1 6:10	45	Immunohistochemical principles:	SN
B −20 −		The technical test approach - post-analytical phase I	I
16:15 - 1 7: <u>00</u>	4530%	Immunohistochemical classification of breast	AVL
# _60_		tumours	
17.00 - 19.00		Social arrangement (optional) - Keglespil (Skittles	<u>3</u>)
Thursday, Septe	mbei	- 21 st	
-100	1		1
08:15 - 09:00	45	Optimization of antibodies, selection, protocols an controls – breastrantimours	d ⁷⁹ SN
09:00 - 09:45	45	Immunohistochemical classification of the nse to crizotinib in patients with EML4-ALK NSCLC. Percent change in tumor burden related to the property of the property of the property of the patients with EML4-ALK NSCLC. Percent change in tumor burden related to the patients of the patient	MV
pretreatment baseline is rep	resented. (R	eputalka Own peptisina a for itulia Qui Engl patitodi 0;363:1693-1703. Copyright	ð 2010,

Optimization of antibodies, selection, protocols and

Optimization of antibodies, selection, protocols and

controls - unknown primary tumours part I

Immunohistochemical classification of the


unknown primary tumour - part II

Coffee

30

45

30





SN

MV




PRELIMINARY

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee
10:00 - 10:15	15	Welcome and introduction
10:15 - 11:00	45	Immunohistochemical principles:
		The technical test approach – pre-analytical phase I
11:05 - 11:50	45	Immunohistochemical principles:
		The technical test approach – pre-analytical phase II

Detection of chromesomanunohistochemical principles: fusion RNA The technical test approach - analytical phase I

changes	The technical test ap	The technical test approach - analytical phase I''		
12:45 - 15:30 45	Lunch			
13:30 - 14:15 45	Immunohistochemica	al principles:	ALK	
EMI 4	The technical test ap		al phase II	
14:20 - 15:05 45	Immunohistochemic	al principles:	ALK ALK	
ALK————————————————————————————————————		proach - post-an	alytica⊬pha <mark>se I</mark>	
15:05 – 15. 25 20	Coffee E15;A20	EML4	ALK	
15:25 - 16: 10 45	Immunohistochemica	al principles:	ALK ALK	
	The technical test ap	proach bost-an	alytica¶pha <mark>se I</mark> I	
16:15 - 17: 00 - 45	Immunohistochemica	al classification o	of breast	
	tumours	_	·	
17.00 – 19.00	Social arrangement ((optional) – Keg	lespil (<u>Skittles</u>)	



Thursday, September 21st

-			
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CN



PRELIMINARY

Wednesday, September 20th

Detestion of fusion p	proteinal, coffee	1 • 4
10:00 - 10:15 15	Welcome and introduction mmunohisto	enemistry
10:15 - 11:00 45	Immunohistochemical principles:	
000000000000000000000000000000000000000	The technical test approach - pre-analytical phase I	ON
11:05 - 11:50 45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON
12:00 – 12:4 5 45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
12:45 - 13:30 45	Lunch	
13:30 - 14: <mark>15 </mark>	Immunohistochemical principles:	MB
00	The technical test approach - analytical phase II	A STATE OF THE STA
14:20 – 15:05 45	Immunohistochemical principles:	SN
ALK fusion 15:05 - 15.25 20	The technical test approach - post-analytical phase I Coffee	
15:25 - 16: protein45	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN
16:15 - 17:00 45	Immunohistochemical classification of breast tumours	AVL
17.00 - 19.00	Social arrangement (optional) - Keglespil (Skittles)	
Thursday, Septemb	er 21 st	
08:15 - 09:00 45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45 45	Immunohistochemical classification of the unknown primary tumour – part I	MV Ventana
09:50 - 10:10 20	Coffee	
10:10 - 10:40 30	Optimization of antibaletestschakprindepend controls – unknown primary tumours part I	egt of fusion partner
10:45 - 11:30 45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and	SN



PRELIMINARY

Wednesday, September 20th Detestion of fusion protein, coffee

Detestion of tusion protein, coffee

260630 1010:00 1 421011 bt	elcome and introduction munohistoshemistry	
000000000000000000000000000000000000000	elcome and introduction [1] [1] [U] [U] [U] [U] [U] [U] [U] [U] [U] [U	
	munohistochemical principles: Jable 1. Antibodies and assessment marks for lu-ALK, rui0利	
	ne technical test approach – pre-analytical phase I Optimal Good Borderline Poor OPS Immunohistochemical principles: Antibodies and assessment marks for id-Ack, ruit approach, ruit approach, ruit approach and assessment marks for id-Ack, ruit approach approach and assessment marks for id-Ack, ruit approach	
	in the technical test approach – pre lanalytical phase II	
	The technical test approach – pre-languyfical phase III	%
	imunohistochemical principles: 1 Biocare Monosan MB 24 7 34% 22%	
	re technical test approach - analytical priase I nch mAb clone ALK1 local Marque 0 0 0 3 -	
	1 Ceil Marque	
	1munohistochemicalopriprii ples: 23 Cell Signaling 6 12 3 2 78% 94%	-
	ne technical test ^m approach analytical phase II 10 11 10 11 10 11 10 11 10 10 100 10	
ALIZ funion		
ALK fusion	e technical test approsed - post analytical phase 0 0	
protein	mAb clone 5A4 imunohistocher MeaP9 rinciples:	
protein	ie technical tes அது நெருக்கு - post-a Marky tream primase II 0 0 1 0	
16:15 - 17:00 45		
10.15 17.00 45	Immunohistochemical chassification of breast of AVL 0 0	
17.00 - 19.00	Social arrangements (optional) – Keglespil (Skittles) 0 0 1 8	THE OC
	mAb clone ALK1	
Thursday, Septembe	r 21 st GA641	
08:15 - 09:00 45	Ontimization of a 799/899/12948 selection protocols and	1 mg
	controls – breast The clone Sp8	
09:00 - 09:45 45	Immunohistochemicaloglassification of the	
	unknown primary tumour – part I	
09:50 - 10:10 20	Coffee 790-4796 ³ 2 Ventana 1 0 1 0 -	
10:10 - 10:40 30	Optimization of a stip of ies; selection of the selection	
	controls – unknown primary tumours part I	
10:45 - 11:30 45	Immunohistochemical classification of the	
	unknown primary) tumour suffice attin Loptimal or good).	Ronch Mark
11:35 - 12:05 30	Unknown primary.) tumour suffice a stain Leptimal or good). Optimization of antibodies, is the optimal protocol settings only, see below 3) RTU system developed for the Ventana Optimization of antibodies, is the optimal protocol settings only, see below 3) RTU system developed for the Ventana Optimization of antibodies, is the optimal protocol settings only, see below 3) RTU system developed for the Ventana Optimization of antibodies, is the optimal protocol settings only, see below 3) RTU system developed for the Ventana Optimization of antibodies, is the optimal protocol settings only, see below 3) RTU system developed for the Ventana Optimization of antibodies, is the optimal protocol settings only, see below 3) RTU system developed for the Ventana Optimization of antibodies, is the optimal protocol settings only, see below 3) RTU system developed for the Ventana Optimization of antibodies, is the optimal protocol settings only, see below 3) RTU system developed for the Ventana Optimization of antibodies, is the optimal protocol settings only, see below 3) RTU system developed for the Ventana Optimization of antibodies, is the optimal protocol settings only and the optimal protocol settings on the optimal p	Denomidik





PRELIMINARY

Wednesday, September 20th


Destection: conf	chromos	Omnalal, coffee	TCII
10:00 - 10:15 10:15 - 11:00		Welcome and introduction F(C)	TZDH
10:15 - 11:00	119 ^{e3} 45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemical principles:	ON 🦱
	EMI (/AI	The technical test approach – pre-analytical phase II	011
12:00 - 124:45	2q23 45 usion	^K Immunohistochemical principles:	МВ
		The technical test approach - analytical phase I	
12:45 - 13:30	45	Lunch	523
13:30 - 14:15	45	Immunohistochemical principles.	мв
		The technical test approach - analytical phase II	10
14:20 - 15:05	45	Immunohistochemical principles:	SN 🤎
		The technical test approach - post-analytical phase I	
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistoche <mark>mical principless</mark>	SN
		The technical test approach - post-analytical phase II	
16:15 - 17:00	45	Immunohistochemical classification of breast	AVL
		tumours	7.02
17.00 - 19.00		Social arrangement (optional) Keglespil (Skittles)	
Thursday, S	Septembe	21 st	/ •
-		Ideogram of chromosome 2	hyb

08:15 - 09:00	7 Y T45)	Optimization of antibodies, selection, protocols and	SN
	Molecular diagn	controls – breast tumours	ing.
09:00 - 09:45	45	Immunohistochemical classification of the	MV
		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN
		controls – unknown primary tumours part I	311
10:45 - 11:30	45	Immunohistochemical classification of the	MV
		unknown primary tumour – part II	I*I V
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CNI





SPEC ALK Dual Color Break Apart Probe hybridized to normal interphase cells as indicated by two orange/green fusion signals per nucleus.






PRELIMINARY

Wednesday, September 20th

Detection of fusion protein, coffee






PRELIMINARY

Wednesday, September 20th

Detection of fusion proteins, coffee






PRELIMINARY

Wednesday, September 20th

09:30 - 10:00 Petection of fusion Arrival, coffee RT PCR based test Rivercome and introduction



e technical test approach - pre-analytical phase I munohistochemical principles:

e technical test approach - pre-analytical phase II munohistochemical principles:

KIF5B-ALK	KIF	5B ALK	e technical test a
12.10	Coil	led-coil domain Tyrosine	inase domain nch
13:30 -	14:15	45	Immunohistochemi
			The technical test a
14:20 -	15:05	45	Immunohistochemi
			The technical test a
15:05 -	15.25	20	Coffee
15:25 -	16:10	45	Immunohistochemi

Immunohistochemi The technical test a 45 Immunohistochemi

> tumours Social arrangement



ON



MV

SN

Thursday, September 21st

30

08:15 - 09:00	45
09:00 - 09:45	45
09:50 - 10:10 10:10 - 10:40	20 30
10:45 - 11:30	45

16:15 - 17:00

17.00 - 19.00

11:35 - 12:05




es, selection, protocols and assification of the ır – part I

es, selection, protocols and nary tumours part I

Immunohistochemical classification of the unknown primary tumour - part II

Optimization of antibodies, selection, protocols and



SN

MV

SN



Program

09:50 - 10:10

10:10 - 10:40

10:45 - 11:30

11:35 - 12:05

Coffee


20

30

45

30

PRELIMINARY



Optimization of antibodies, selection, protocols and


Optimization of antibodies, selection, protocols and

controls - unknown primary tumours part I Immunohistochemical classification of the

unknown primary tumour - part II




Program Wednesday



- 11:05 11:50
- 12:00 12:45
- 12:45 13:30
- 13:30 14:15
- 14:20 15:05
- 15:05 15.25
- 15:25 16:10
- 16:15 17:00
- 17.00 19.00

Thursday, Se

- 08:15 09:00
- 09:00 09:45
- 09:50 10:10
- 10:10 10:40
- 10:45 11:30



ROS1

- Crizotinib 4
- Cabozantinib ²
- Ceritinib²
- Lorlatinib²
- DS-6051b ¹



PRELIMINARY

Wednesday, September 20th

09:30 - 10:00	-	Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SWS fusion partners
10:15 - 11:00	45	Immunohistochemical principles:	Transmembrane domain
		The technical test approach - pre-analytical phase I	Ortacullaular domian Tyrosine kinase domain
11:05 - 11:50	45	Immunohistochemical principles:	
	H.H.H.H.H.	The technical test approach pre-analytical phase II	ON
12:00 - 12:45	45-	Immunohistochemical paralles	
		The technical test approach - analytical phase I	MB
12:45 - 13:30	45	Larch P13K	
13:30 - 14:15	45RA	Immunohistochemica principles:	MD
	1	The technical test approach - analytical phase Her	MB _{k1}
14:20 - 15:05	45	Immunohistochemical principles keleton	SN
	RA	The technical test approach - postHandlytical phase I	
15:05 - 15.25	20 👈	Coffee	AKT
15:25 - 16:10	45	Immunohistochemical principles otein: Transformat	iorSNI 🛨
	ME	The technical test approach - post-analytical phase II	an a
16:15 - 17:00	45	Immun <mark>o</mark> histoc <mark>hemicalⁱclass</mark> ification of breast _{Apoptosis}	AVL
	MAN	tu <mark>mours</mark> β- catenin	
17.00 - 19.00	MA	Social arrangement (optional) - Keglespil (<u>Skittles</u>)	1
Thursday, Sep	temb <mark>e</mark>	r 21 st N-catenin	Translation
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	C
	Prolife	controls – breast tumours	SN Capacity increased
09:00 - 09:45	& Sur	Immunohistochemical classification of the	MV
		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN
		controls – unknown primary tumours part I	SIN
10:45 - 11:30	45	Immunohistochemical classification of the	MV
		unknown primary tumour – part II	1°1 V
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN



PRELIMINARY

Wednesday

10:15 - 11:00

11:05 - 11:50 🖁

12:00 - 12:45

12:45 - 13:30

13:30 - 14:15

14:20 - 15:05

15:05 - 15.25 15:25 - 16:10

16:15 - 17:00 %

17.00 - 19.00

September 20 mor responses to crizotinib



45 Immunohistochemical principles: ON

The technical test approach - pre-analytical phase I

A Response munohistochemical principles: ON The technical test approach propre analytical phase of the therapy Immunohistochemical principles: 45 MB The technical test approach - analytical phase I 45 Lunch 45 🖥 Immunohistochemical principles: MB The technical test approach - analytical phase II Immunohistochemical SN The technical test approach post-analytical phase I 20 ਹੈ Goffee Immunohistochemical principles! 45

45 Immunohistochemical classification of breast **AVL** tumours

Social arrangement (optional) - Keglespil (Skittles)

-The technical test approach - post-analytical phase II

09:00 - 09:45

09:50 - 10:10

10:10 - 10:40

10:45 - 11:30

Thursday, September 21st
Overall response rate 72% (6% CR, 66% PR).

15 Optimization of antibodies, selection, protocols and Mediantrime bloase 7.9 weeks (range, 4%). 4\frac{1}{3} - 32.0



Coffee 20

30 Optimization of antibodies, selection, protocols and SN controls - unknown primary tumours part I

Immunohistochemical classification of the 45 MV unknown primary tumour - part II

11:35 - 12:05 30 Optimization of antibodies, selection, protocols and





SN



10:45 - 11:30

11:35 - 12:05

PRELIMINARY

Wednesday, September 20th

45

30

09:30 - 10:00 Arrival, coffee efection of chrongs Welcome and introduction 'Immunohietestiem paticities ion RNA **changes** 11:05 - 11:50 The technical test approach – pre-analytical phase I 45 Immunohistochemical principles: The technical test approach pre-analytical phase II Immunohistochemical principles: 12:00 - 12:45 The technical test approach analytical phase I Chr 5 12:45 - 13:30 45 Lunch 45 13:30 - 14:15 Immunohistochemical principles: The technical test approach - analytical phase II ROS1 14:20 - 15:05 **45** ROS1-CD74 Immunohistochemical principles The technical test approach - post-analytical phase I 20 15:05 - 15.25 Coffee 15:25 - 16:10 45 Immunohistochemical principles: The techi CD74-ROS1 tical phase II 16:15 - 17:00 45 **Immunol** reast tumours 17.00 - 19.00Social arı pil (Skittles) Thu **21**st 08:15 Optimiza⁻ and controls -09:00 **Immunol** unknown primary turnour - par 09:50 Coffee 10:10 - 10:40 30 Optimization of antibodies, sel and


controls - unknown primary tumours part 1

Optimization of antibodies, selection, protocols and

Immunohistochemical classification of the

unknown primary tumour - part II


Detection of fusion protein



SN

SN


MV






PRELIMINARY

Wednesday, September 20th



SN controls – breast tumours Immunohistochemical classification of the MV 45 Other luna unknown primary tumour - part I carcinoma e.g. squamous, 0 20 Coffee 30 Optimization of antibodies, selection, protocols and SN controls - unknown primary tumours part I 45 Immunohistochemical classification of the 10:45 - 11:30 MV unknown primary tumour - part II 11:35 - 12:05 **30** Optimization of antibodies, selection, protocols and SN





HER2

- Trastuzumab emtansine²
- Afatinib ²
- Dacomitinib²

ROS1

- Crizotinib 4
- Cabozantinib ²
- Ceritinib²
- Lorlatinib ²
- DS-6051b ¹

BRAF

- Vemurafenib²
- Dabrafenib²

RET

- Cabozantinib²
- Alectinib 2
- Apatinib²
- Vandetanib²
- Ponatinib ²
- Lenvatinib ²

NTRK1

- Entrectinib ²
- LOXO-101²
- Cabozantinib ²
- DS-6051b 1


Scientifia Alva 35 in Lule 2 and 52015



11:35 - 12:05

PRELIMINARY

Wednesday, September 20th



controls – breast tumours

45 Immunohistochemical classification of the unknown primary tumour – part I

20 Coffee

30 Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I

10:45 – 11:30

45 Immunohistochemical classification of the

controls – unknown primary tumours part I

45 Immunohistochemical classification of the unknown primary tumour – part II

Optimization of antibodies, selection, protocols and




MV

SN

MV

Patient selection in lung cancer: Evolution over time





PRELIMINARY

Wednesday, S	Septen	nber 20 th T-cell	
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemical principles:	ON
		The technical test approach - pre-analytical phase II	OIL
12:00 - 12:45	45	Immunobistechemical principles:	МВ
12.45 12.20	45	The technical test approach - analytical phase I +	
12:45 - 13:30	45 45	Lunch	
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	MB
14:20 - 15:05	45		all recentor
14.20 15.05	75	The technical test approach - post-analytical phase I	ell receptor
15:05 - 15.25	20	Coffee -	
15:25 - 16:10	45	Immunohistochemical principles:	CN
		The technical test approach - post-analytical phase Trong	antigen
16:15 - 17:00	45	Immunohistochemical classification of breast	AVL
		tumours	\ \ _
17.00 - 19.00		Social arrangement (optional) – Keglespil (Skittles)	
Thursday, Sep	tembe	r 21st	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	SN
		controls – breast turnours	
09:00 - 09:45	45	Immunohistochemical classification of the	MV
00.50 10.10	20	unknown primary tumour – part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the	
10.75 11.50	75	unknown primary tumour - part \$£LC cell	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CN



PRELIMINARY

Wednesday, S	epten	nber 20 th T-cell	4.
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach - pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemical principles:	ON
10.00 10.15		The technical test approach - pre-analytical phase II	
12:00 - 12:45	45	Immunohistochemical principles:	МВ
12.45 12.20	4.5	The technical test approach - analytical phase I +	
12:45 - 13:30	45 45	Lunch	
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	MB
14:20 - 15:05	45		II rocenter
14.20 - 15.05	73	The technical test approach - post-analytical phase I	Il receptor
15:05 - 15.25	20	Coffee -	
15:25 - 16:10	45	Immunohistochemical principles:	
	_	The technical test approach post-analytical phase IPra	intigen .
16:15 - 17:00	45	Immunohistochemical classification of breast	AVL
		tumours	AVL
17.00 - 19.00		Social arrangement (optional) – Keglespil (Skittles)	
Thursday, Sept	embe	r 21 st	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	SN
Dradictiva	m	controls - breast turnours	SIN
LOP CO PO FINA	1 45 a	In Suhohistochemical classification of the	MV
		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN
10.45 11.20	4-	controls – unknown primary tumours part I	
10:45 - 11:30	45	Immunohistochemical classification of the	MV
11:35 - 12:05	30	unknown primary tumour – part LC cell Optimization of antibodies, selection, protocols and	
11.33 - 12.03	30	opulmization of antibodies, selection, protocols and	SN



PRELIMINARY

man Rao, M.D., Kai 45 Hotta, Minimum ohistochemical classification of the

unknown primary tumour - part II


Optimization of antibodies, selection, protocols and

Wednesday, September 20th


for the KEYNOTE-024 Investigators

30

11:35 - 12:05



MV





Program		PRELIMINARY	
Wednesday		20 th	
09:30 - 10:00 10:00 - 10:15 10:15 - 11:00		ome and introduction unohistochemical principles: une technical test approach – pre-analytical phase I	SN ON
11:05 11:50	45	Immunohistochemical principles: The technological principles: The technological principles: The technological principles:	r and immune cells
12:00 - 12:45	45	Immunohistechemical principles: The technical test approach - analytical phase I	(™Es and ICs)
12:45 - 13:30	45	Lunch	THE SECTION AND SECTION AS A PROPERTY OF SECTI
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	МВ
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN
16:15 - 17:00	745 7	Immunohistochemical classification of breast tumours	AVL
17.00 - 19.00	A PA	Social arrangement (optional) - Keglespil (Skittles)	The second second
Thursday, Se	eptembe	r 21 st	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10	20	Coffee Immunhistological staining f	or PDL1
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN



PRELIMINARY

Wednesday, Sep	tember 20 th	E1L3N antibody	SP142 antibody
09:30 - 10:00	Arrival, coffee	9 10 10 10 10 10 10 10 10 10 10 10 10 10	1 to 1000 to 1
10:00 - 10:15 1	5 Welcome and introduction	SN	100
10:15 - 11:00	5 Immunohistochemical princip		Section 2 1 Section 2
	The technical test approach -	– pre-analytical phase I	
11:05 - 11:50	5 Immunohistochemical princip		
10.00	The technical test approach -	– prg-analytical phase II	
12:00 - 12:45	5 Immunohistochemical princip	The state of the s	The state of the s
12:45 - 13:30	The technical test approach - Lunch	- analytical phase I	
Cambridge A Cambridge A Cambridge Company	5 Immunohistochemical princip	older.	The state of the s
13.30 - 14.13	The technical test approach -	IVI H	3
14:20 - 15:05 4	5 Immunohistochemical princip		100 um
11.20	The technical test approach -		100 µпі
15:05 - 15.25 2	O Coffee	, ,	
15:25 - 16:10	5 Immunohistochemical princip	otes:	
	The technical test approach -	THE REPORT OF THE PROPERTY AND PROPERTY AND ADDRESS OF THE PROPERTY OF THE PRO	
16:15 - 17:00	5 Immunohistochemical classif	ication of breast	
	tumours	Salah Palah A	
17.00 - 19.00	Social arrangement (optional	l) – Keglespil (Skittles)	
Thursday, Septem	ber 21st	sitiv	
	5 Optimization of antibodies, s	election, protocols and	
08.15 - 09.00	controls - breast tumours	SN	PARTY AND
09:00 - 09:45	5 Immunohistochemical classif	ication of the MV	A CONTRACTOR OF THE PARTY OF TH
	unknown primary tymour – p		a de la de la companya de la company
09:50 <u>- 10</u> :10 2	0 Coffee		100000000000000000000000000000000000000
10:10 - 10:40	O Optimization of antibodies, s	electionsoprotocols and	100 μm
	controls – unknown primary	tumours part I	
10:45 - 11:30 4	5 Immunohistochemical classif	IVIV	405
	unknown primary tumour – p	part II	105
11:35 – 12:05 3	O Optimization of antibodies, se	election, protocols and SN	



PRELIMINARY

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON
1Table 1 11:50	45	Immunohistochemical principles:	ONIL cell lung cancer (NSCI C)

Results of randomised phase III trials recomment the the the properties of the prope

12in20of-træ2tr45nt	DA5 Immunohistoiahemical principtes: 1 selection ORR	MRPFS (months)	OS (months)	
12.45 12.20	The technical test approach - analytical phase I	Median HR	Median HR	
1 2:45 - 13:30 1 5 !30 - 14:15	Pe 45 Lunch Pe 45 rolizμሞት unohis Kočhe mied principies % 45%	10.4 0.50	NR 0.60	
	Nivoluma the technical electrosphase II ²⁶ %	$MB_{4.2}$ 1.15	14.4 1.02	
142200 db gyzo.1005	Penbrolizumahunghiskerneten (12) principles 18%	4 0.79	12.7 0.61	
	Pembrolizmae technicat rest approach - post analytical phase 1	$SN_{5.2}$ 0.59	17.3 0.50	
15:05 - 15.25	Nizoluma Coffee Checkmate-017 No 20%	3.5 0.62	9.2 0.59	
15:25 - 16:10	Ni 43 uma mmunohistochemica 7 principles:	2.3 0.92	12.2 0.73	
	Atezolizumah technical test approach - post-analytical phase 11	SN _{2.8} 0.95	13.8 0.73	

17. 00 utof 19:00% was used for inc Social larrange rae of the (notional for Inc Social larrange rae of the continual for Inc Social larrange rae of the con

Thursday, September 21 sg.

08:15 - 09:00 45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45 45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10 20	Coffee	
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30 45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and	SN



PRELIMINARY

Wednesday, September 20th

• •			
09:30 - 10:00	Arrival, coffee		
10:00 - 10:15	15 Welcome and introduction	SN	
10:15 ^{Fest} 11:00	45 Immunohistochemical principles: Ventana seខេងនាំ(ជ) test apako azb (2) re-ana	alytica bakos28I8 (3)	Ventana SP142 (4)
11:05 - 11:50	45 Immunohistochemical principles:	ON	
Developed as	Durvahentechnical test approach umatrement	ekytica NRVARRAJI	Atezolizumab
12:00 - 12:45	45 Immunohistochemical principles:		(0 (1)
companion diagno		cal pha(\$\frac{1}{2}tol-Niyers Squibb)	(Genentech)
.2:45 - 13:30	45 Lunch		
13:30 - 14:15	45 VENTARALBERALBERALBERS:	Dako Autostainen	VENTANA BenchMark
Instrument	The technical test apparation and stained lythic	ka4&phase 11 Link 48	ULTRA
14:20 - 15:05	45 ULTRAmunohistochemical principles:	CN	ULIKA
5:05 - 15.25 PD-L1 antibody 5:25 - 16:10	The technical test approach - post-an Clone SP263 (rabbit Clone 22C3 (mouse	Clone 28-8 (rabbit	Clone SP142 (rabbit
5:25 - 16:10	45 mondconal nohistochem ical principles: The technical test approach - post-an	monoclonal) SN nalytical phase II	monoclonal)
.6:15 - 17:00	45 Immunohistochemical classification of	of broact	Tumor cells and tumor-
Compartment	Tum bu red une mbrane Tumor cell membrane		
7.00 - 19.00	Social arrangement (optional) – Keg	lespil (<u>Skittles</u>)	infiltrating immune cells
「hufstdấy) fSept	- : /0, -00 /0 0: 10::::0:	cells ≥1%; ≥5%; ≥10% of tumor	≥50% of tumor cells
)8:1 5 high 0900 0	45 ≥25% of thmore fells (5) antibodies, selection controls – breast tumours	, protocols and cells (7) SN	or ≥10% of tumor area
09:00 - 09:45	45 Immunohistochemical classification of unknown primary tumour – part I	of the MV	
09:50 - 10:10	20 Coffee		
.0:10 - 10:40		protocols and	
0.10 - 10.40	Optimization of antibodies, selection controls – unknown primary tumours		
.0:45 - 11:30	45 Immunohistochemical classification	•	
.0.45 - 11:30	unknown primary tumour – part II	or the MV	
11:35 - 12:05	30 Optimization of antibodies, selection	protocols and	
11.00 12.00	optimization of antibodies, selection	, protocois and CN	



PRELIMINARY

Wednesday, S	Septer	nbear2@e⁴of	Ventana	Dako	Dako
09:30 - 10:00		stavalnof6%	SP263	22C3	28-8
10:00 - 10:15	15	Welcome and intro	duction	THE PROPERTY OF THE PARTY OF TH	SNEWWOOD
10:15 - 11:00	45	Immunohistochem	ical principles:	The state of the	ON
		The technical test	approach – pre-anal	ytical phase I	CIV
11:05 - 11:50	45	Immunohistochem	TO THE THE CASE OF THE PARTY OF THE RESIDENCE OF THE		ON
			approach – pre-anal	ytical phase II	Oliver and the same of the sam
12:00 - 12:45	45	Immunohistochem	The state of the s		MB
			approach - analytica	phase I	
12:45 - 13:30	45	Lunch		The state of	100 May 100 Ma
13:30 - 14:15	45	Immunohistochem		ALCOHOL SIX BOTH	MB
44.00 45.05		•	approach - analytica	l phase II	STATE OF THE PARTY OF
14:20 - 15:05	45	Immunohistochem	THE RESERVE OF THE PARTY OF THE	67 A	SN
15.05 15.25	20		approach - post-ana	ytical phase I	
15:05 - 15.25	20	Coffee			
15:25 - 16:10	45	Immunohistochem		utical phase II	SN
16:15 - 17:00	45		approach - post-ana ical classification of	Co. C. Park St.	67 35
10.13 - 17.00	45	tumours	ical classification of	Diedst	AVL
17.00 - 19.00			t (optional) – Kegle	snil (Skittles)	Of the second
			e (optional) regio	Spir (<u>spricies</u>)	25 - Sta
Thursday, Sept	embe	er 21 st	STORY CONTRACTOR OF THE PARTY O	NAMES OF THE OWNER OWNER OF THE OWNER	NATION CONTRACTOR AND ADDRESS OF THE PARTY O
08:15 - 09:00	45	Optimization of an	tibodies, selection,	protocols and	SN
		controls - breast to	umours		SIV
09:00 - 09:45	45	4000	ical classification of	the 📉	MV
		unknown primary t	umour – part I		
09:50 — Lulighed Linkoffirst January 10, 2	017; DOI <u>2.0</u> 8/1078				
10: Tarcer Thorapy: Clinical 40	30	Optimical on of an	tibodies, selection,	protocols and	SN
Agreement between Progra	ammed Cell	De@ontrols unknow!	n primary tumours	part I	
	in Non-Sma	i di cell i i i un un o i i scoci i e i i	icai ciassification oi	the	MV
Lung Cancer & Marianne J. Ratgliffe ¹ , Alan Sharpe ² , Anita Mi	dha ¹ , Cr <u>aig Ba</u> rker ² .	unknown primary t	umour – part II		
11 Pagi Sporer ² , Hythan A(nasi ³ , Marlon C. Re	belatto 3.0 Jill W	Mariette Scotti Palker Optimization of an	tibodies, selection,	protocols and	SN

108



Prog ram		PRELIMINARY
Wednesday, S	epter	mber 20 th
09:30 - 10:00		Arrival, coffe
10:00 - 10:15	15	Welcome and introduction SN
10:15 - 11:00	45	Immunohistochemical principles:
Cyta	oloa	
11:05 - 11:50	45	Immunohis Contrectured reprinciples: Periferal tumor
		The technical test approach – pre-analytical phase II Immunohistochemical principles:
12:00 - 12:45	45	
12.45		ine technical testical program, - analytical phase I
12:45 - 13:30	45	Editori
13:30 - 14:15	45	Immunohistochestericiples: biopsi The technical technical properties and the second se
14:20 - 15:05	45	The technical test approach - analytical phase II Immunohistochemical principles:
14.20 - 15.05		The technical test approach - post-analytical phase I
15:05 - 15.25	20	Coffee
15:25 - 16:10	45	Immunohistochemical principles:
16:15 - 17:00	45	The technical test approach - post-analytical phase II Immunohistochemical classification of breast
		tumours
17.00 - 19.00		Social arrangement (opinisi alpetastic glespil (Skittles)
Thursday, Sept	embe	er 21 st EBUS
08:15 - 09:00	345	Optimization of antibodies, selection, problems and
		controls – breast tumours
09:00 - 09:45	45	Immunokistochemical classification of the
		unknown primaryortelmanualehipart I
09:50 - 10:10	20	Coffee M from metastasis suspekte
10:10 - 10:40	30	Optimization of a (Milotodies) esetection protosols and SN
10,45 11,30		controls – unknown primary turnours part 1
10:45 - 11:30	45 _Q	Immunohistochemical classification of the Operahel 20%
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and



PRELIMINARY

Wednesday, Septe	m Beseapotia rticle		
09:30 - 10:00	Arrival, coffee		
10:00 - 10:15 15	Welcome and introduction	SN	
	n of milling is the state of th	ON	
^{11:05} Lung Assessed W	/ithmunohistochemical principles. The technical test approach - pre-analytical phase II	ON	
	1 Ilhkur24st3pleatio Principles: The technical test approach analytical phase I Lunch	МВ	
12:45 – 13:30 Birgii G. Sköv, I	Lunch		
13:30 - 14:15 45	Immunohistochemical principles:	asd MB me	nt is feasible on cytologic material
14:20 - 15:05 45	The technical test approach - analytical phase II Immunohistochemical principles: With the tested assay The technical test approach - post-analytical phase I	s using c na SN al.	utoffs for positivity similar to those
15:05 – 15 <u>.25</u> 20	Coffee		
15:25 - 16TAPLE 3. IHC 45ni Thresholds of PD-L1	ng ច្រាលអាខ្យក់ថ្ងៃស្វារី គេ periodiplas d With Histologic Sample Po រីក្រេច់២ echnical test approach - post-analytical phase II	es by Agre	eement Statistics for Different
16:15 - 17:00 45	Immunohistochemical @lassifitatlosios onesst	AVL	Cutoff ≥ 50% Positive Cells
PD-L1 IHC 22C3pharn	_{nDx} tumours	AVL	
17.00 – 19.00 verall agreement Positive percent agree	Social arrangement (optional) (76ke) glespil (Skittles)		94 (87-98) 100 (96-100)
Thursday, September			93 (86-97)
08:15 - 09:00 45 PD-L1 IHC 28-8 pharm	Optimization of antibodies is election up to to color and on the controls - breast, tumours	ells SN	Cutoff ≥ 10 % positive cells
09:00 − 09:45 sitive percen45 rea	emelimmunohistochemical) classification of the 1 (83-95) emelimknown primary (termour – part I 98 (93-100)	MV	90 (81-94) 79 (70-87) 95 (88-98)
09:50 - 10:10 alues are repre 20 ed	as reoffee CI.		· · · · · · · · · · · · · · · · · · ·
10:10 - 10:46 indicates confidence	interval, IHC, immunohistochemistry; PD-L1, programmed cell death ligand-1, Optimization of antibodies, selection, protocols and	CN	
	controls – unknown primary tumours part I	SN	
10:45 - 11:30 45	Immunohistochemical classification of the unknown primary tumour – part II	MV	
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and	SN	



PRELIMINARY


Wednesday	Y,NoSeptemberca 20th control 31/08/2019 13.01
09:30 - 10:00	Arrival, coffee
10:00 - 10:15	Welsome Moduletrodustigments Protocols Controls Events Login
10:15 - 11:00	Immunohistochemical principles:
	The technical test approach – pre-analytical phase I
11:05 - 11:50	45 Immunchistochemical principles:
	The technical test approach - pre-analytical phase II Nordic Workshop in Diagnostic Immunohistochemistry
12:00 - 12:45	45 Immunohistochemical principles: 2-4 Act 2019: Aalborg, DK
	I ne technical test approach a analytical phase I 6th Academy of Diagnostic
12:45 - 13:30	45 Lunch Immunohistochemistry 9-11 Oct 2019: Krakow, Poland
13:30 - 14:15	4th No Mark Conference on Applied
1122 1525	The technical test approach - analytical phase II Immunohistochemistry 2-5 Jun 2020: Aalborg, Denmark
14:20 – 15:05	A 43 Turriduonistochemicar principles.
15:05 - 15.25	The technical test approach - post-analytical phase I Coffee
15:25 - 16:10	Run 57, B28, H16, C6
13.23 - 10.10	The technical test approach - post-analytical phase II Protocol submission deadline SN 4 Sep 2019 Slide circulation
16:15 - 17:00	15 Immunohistoshomical classification of broast
10.15 17.00	turnours AsMode return deadline
17.00 - 19.00	Social arrangement (optional) – Keglespil (Skittles) 11 Oct 2019 Publication of results
Thursday C	6 Dec 2019
inursday, S	eptember 21 st D HC for PAX8 in two Jaboratories: Lab 1 (A/C): Optimal results in Fallopian tube and Renal Q Questions
08:15 - 09:00	clear celegration of the control of the clear celegration of the celegrat
	dy false negative representations) or contact us
09:00 - 09:45	45 Immun@ajstpchemisal@assification of the MV
00 50 40 40	9-Jul-2019 unknown primary tumour – part I
09:50 - 10:10	The reset of for the office of and C5 are now available on the website. Individual
10:10 - 10:40	results c 30 e see Opter has it is not antibodies, selection, protocols and SN
10.45 11.20	controls – unkrational classification of the
10:45 - 11:30	unknown primary tumour - part II
11:35 - 12:05	20 Optimization of antibodies, selection, protocols and
11.55 - 12.05	SN

020	
NordiQC	

Drogram		Table 2. Assessment marks	for IHC a	ssays and antibodies i	un C9, P	D-L1 TP	S/CPS (KE	YTRUDA	(®)		
Program		CE-IVD / FDA approved PD-L1 assays	n Ve	endor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²	
Wednesday, Se	epter	nber 729th SP263, (VRPS)3	42 Ve	entana/Roche	29	9	4	-	91%	69%	
09:30 - 10:00		rmAb clone SP263, Arri\na1 ;4 005(£06)⁴	2 Ve	entana/Roche	-	-	1	1	-	-	
10:00 - 10:15	15	Welgangspagnesjintrod	uction	η tana/Roche	8	4	1	SN	92%	62%	
10:15 - 11:00	45	Imm <u>ប្បាំក្នុង</u> ្ឃ៉ូឡិស្ត្រៀemic	al ıpri	nciples:	-	-	-	ОN	-	-	
		The technical test, ap	oproa	ch – pre-anal	ytiçal	phase	e I ₄	-	83%	22%	
11:05 - 11:50	45	Imm <u>ilifiahistochemi</u> The feethies test a	al pri	nciples:	2	3	²	ΟŧΝ	56%	22%	
12.00 12.45	45	Ine rechnical test at make clone 22C3 pharmDX, Immuno vistochemic	oproa	CN – pre-anal	yticai 17	pnase	- 5 II	_	100%	81%	
12:00 - 12:45	45	The confidence in the confiden				ъ Т	2	MB	71%	29%	
12:45 - 13:30	45	LUn(Thab clone 28-8 pharmDX,				e P	2		71%	29%	
13:30 - 14:15	45	SK005 (VRPS) ³	. Z Da	ako/Agilent	2	-	-	-	-	-	
13.30 - 14.13	45	The Antibodies ⁵ for laboratory developed PD-L1 assays, concentrated antibodies	n Ve	endor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²	
14:20 - 15:05	45	Immwhomistochemic	al³bPi	rendres:	10	21	5	2	82%	26%	
		The rections E113N test at	4 " Ce	ell Signaling	ytical	րկas	e I ₋	SN	-	- /	
15:05 - 15.25	20	Coff end b clone BSR90		ordic Biosite	-	1	-	-	-		
15:25 - 16:10	45	Immun6histochemic	al pe	ocare Machaesis	3	1	-	- CN			
		The technical test ap	opro	ሮή - post-ana	ytical	pḥas	e I I	SŅ	20		3
16:15 - 17:00	45	rmAb clone SP142 , '' Immunonistochemic rmAb clone ZR3	al ₁Clæ	issingation of	brea	ist_	2	AVL		_ (
		tumourc Ready-To-Use antibodies	1 Zy n Ve	torried systems	Optimal		Borderline	Poor	Suff. ¹	OR ²	
17.00 - 19.00		Social Aarhangement						1	85%	62%	A.
Thursday, Septe	embe		20 Ve	entana/Roche	12	6	1	1	90%	60%	
08:15 - 09:00	45	Optimut the of anti-	bodie	sposelection,	protc	cols	and	SÑ	-	-	
		control suc44 breast tui	mque	S nomeMe	-	-	1	SIV -	-	-	
09:00 - 09:45	45	Immunahistochemic	:ai ˌcia	issification of	the	1	-	Μ̈́V	-	-	
		unki lō;wn`brimary tu	l <mark>mour</mark> 2 Ma	r – part I	2		_		_	_	
09:50 - 10:10	20	Coff MAB-0854									
10:10 - 10:40	30	Optimization of anti						SŅ	-	-	
		controls – unknown	-	-	47%	73 35%	30 14%	4%	32%		
10:45 - 11:30	45	IMMUNOMOSTOCACIONIC									
44.05.45.55		unkacowan panamanyating Optimitation of the control	Ab: rabbit m	uct used in someliante to protoco duct applied either on the vendo onoclonal antibody.	oI settings, p r recommen	olatform and ded platform	package insert n(s) or other pla	tforms.			
11:35 - 12:05	30	Optimization of anti-	bodie	s, selection,	proto	cols	and	SN			



11:35



Optimization of antibodies, sciention, protocols and



PRELIMINARY

9				
Wednesday, Se	pten	nber 20 th T-cell		
09:30 - 10:00		Arrival, coffee		
10:00 - 10:15	15	Welcome and introduction	SN	
10:15 - 11:00	45	Immunohistochemical principles:	ON	
		The technical test approach – pre-analytical phase I	ON	
11:05 - 11:50	45	Immunohistochemic <mark>al principles:</mark>	ON	
10.00 10.15		The technical test approach - pre-analytical phase II		
12:00 - 12:45	45	Immunohistochemical principles:	МВ	
12:45 - 13:30	45	The technical test approach - analytical phase I +		
13:30 - 14:15	45 45	Immunohistochemical principles:		
13.30 - 14.13	45	The technical test approach - analytical phase II	MB	
14:20 - 15:05	45		ell recepto	
11.20 10.00		The technical test approach - post-analytical phase I	SN	
15:05 - 15.25	20	Coffee		
15:25 - 16:10	45	Immunohistochemical principles:	CN	
		The technical test approach post-analytical phase pro-	antigen	Г.,4,,,,,,
16:15 - 17:00	45	Immunohistochemical classification of breast	AVL	Future:
17.00 10.00		turnours		
17.00 – 19.00		Social arrangement (optional) – Keglespil (Skittles)		
Thursday, Septe	mbe	r 21st		
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	_c Pr	redictive marker
		controls - breast turnours	SN I	edictive marker
09:00 - 09:45	45	Immunohistochemical classification of the	MV	Tumor Mutational Burden
		unknown primary tumour – part I		
09:50 - 10:10	20	Coffee		TMB
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN	Micro Satellite Instability
10:45 - 11:30	45	controls – unknown primary tumours part I Immunohistochemical classification of the		
10.47 - 11.30	73	unknown primary tumour – part LC cell	MV	MSI
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and		
		The second and	SN	



PRELIMINARY

Wednesday, S	Septen	mber 20 th T-cell	Future:
09:30 - 10:00		Arrival, coffee	i dear e.
10:00 - 10:15	15	Welcome and introduction SN	
10:15 - 11:00	45	Immunohistochemical principles: ON	
		The technical test approach – pre-analytical phase I	
11:05 - 11:50	45	Immunohistochemical principles:	Predictive marker
		pembronzumab	redictive marker
12:00 - 12:45	45	Immunohistechemical principles:	
10.45 10.00	4-	The technical test approach - analytical phase I	Evaluation of immune respons
12:45 - 13:30	45	Lunch	
13:30 - 14:15	45	Immunohistochemical principles:	
14.20 15.05	45	The technical test approach - analytical phase II	
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	or
15:05 - 15.25	20	Coffee -	
15:25 - 16:10	45	Immunohistochomical arinciples	
13.23 10.10	-15	The technical test approach post-analytical phase III ph	
16:15 - 17:00	45	Immunohistochemical classification of breast	
		tumours	
17.00 - 19.00		Social arrangement (optional) - Keglespil (Skittles)	
Thursday, Sept	tembe	er 21st zumab	
08:15 - 09:00	45	Ontimization of antibodies, selection, protocols and	
		controls – breast turnours	
09:00 - 09:45	45	Immunohistochemical classification of the MV	
		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and SN	
		controls – unknown primary tumours part 1	
10:45 - 11:30	45	Immunohistochemical classification of the MV	
44.05.45.55		unknown primary tumour – part\sclc cell	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	




PRELIMINARY


Wednesday, September 20th

09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON
12:00 - 12:45	45	Immunohistochemical principles: The refireal test against dical gorit	η ľ Υη
12:45 - 13:30	45	Lunch	
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	МВ
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN
16:15 - 17:00	45	Immunohistochemical classification of breast tumours	AVL
17.00 - 19.00		Social arrangement (optional) – Keglespil (<u>Skittles</u>)	

Thursday, September 21st


08:15 - 09:00 45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45 45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10 20	Coffee	
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30 45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and	SN









Pleura effusion Cell Block





P2-lin (2763)

118






Pleura effusion Cell Block

Mutation analysis

KRAS G12C




2. line TKI







EBUS CellBlock



CK5/6, CK7 and P40+




PD-L1 (22C3)







EBUS Cell Block



CK5/6 and P40+





PD-L1 (22C3)







Coarse needle biopsy







PDL1 (22C3)






Coarse needle biopsy

Mutation analysis


EGFR exon 19 del




I. line TKI










Large tumor intra uterine Endometrial cancer (yolk sac tumor)

Patient selection in lung cancer: Evolution over time





PRELIMINARY

